Cross reactive microbial peptide cancer vaccine and t cell receptors reactive thereto
Patent Information
- Application Number
- PCT/EP2024/057967
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-23
- Filing Date
- 2024-03-25
- Publication Date
- 2024-12-05
AI Technical Summary
Current cancer treatments face challenges in breaking immune tolerance to self-antigens expressed within tumors, limiting the effectiveness of cancer vaccines, as many tumor antigens are not mutated and thus immunogenic, and T cells with reactivity against self-antigens are eliminated by central tolerance mechanisms.
Development of bacterial and gut microbiota-derived peptide sequences that stimulate T cell clones to recognize and target tumor antigens, including the use of specific peptide sequences and T cell receptor polypeptides to expand T cell populations capable of cross-recognizing tumor-derived antigens, particularly in glioblastoma.
The proposed solution enhances the immune response against tumor antigens by stimulating T cell clones and bulk T cell populations, potentially leading to improved anti-tumor immunity and treatment outcomes for cancers like glioblastoma.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001] Cross Reactive Microbial Peptide Cancer Vaccine and T Cell Receptors Reactive Thereto
[0002] This application claims the right of priority of European patent application 23163878, incorporated herein by reference in its entirety.
[0003] The present invention relates to peptide vaccines generated from cross reactive microbial peptides presented to tumour associated T cells, and to T cell receptor (TCR) polypeptides capable of recognizing such peptides.
[0004] Background of the Invention
[0005] The treatment of cancer includes the three classical “pillars” surgery, radio- and chemotherapy. With cancer immunotherapy a fourth pillar emerged. The introduction of immune checkpoint inhibition led to advances in survival rates in several cancers and demonstrated that unleashing immune effector mechanisms can result in elimination of tumour cells. In parallel, numerous approaches are being explored to go a step further and vaccinate patients with tumour neoantigens, with the final goal to induce tumour-specific T cells that mount a precise and effective immune response against the tumour. Several lines of evidence indicate that tumour vaccination will be feasible, particularly in so-called "hot" tumours with high numbers of mutations and strong immune cell infiltrates such as melanoma, however, numerous hurdles still need to be overcome. Among these, the relatively low immunogenicity of many tumour antigens, particularly if they are not mutated, impedes the induction of strong anti-tumour T cell responses, since T cells with reactivity against self-antigens are eliminated by central tolerance mechanisms in the thymus. Hence, the more foreign an antigen "looks" to T cells, the more likely it will induce a strong immune response. In agreement with this, reports about patients, whose tumour either shrank substantially during an infection with a bacterial or viral pathogen or disappeared completely, indicated that protective immune responses against pathogens may also target the tumour, most likely by T cell cross-reactivity between tumour- and pathogen-derived antigens. Supporting this notion, several studies have demonstrated improved responses to immune checkpoint inhibitors in the presence of certain gut bacteria. Adoptive transfer of Bacteroides fragilis-specific T cells to germ-free mice restored the response to anti-CTLA-4. In keeping with this, anti-tumour responses can be elicited by cross-reactivity between commensal bacteria and tumour antigens (Bessell et al., JCI Insight 5, 135597 (2020)). Furthermore, it has been demonstrated that CD8+ T cells can cross-recognize a peptide from Enterococcus hirae bacteriophage and a tumour antigen by molecular mimicry. One approved therapy against bladder cancer, an extract of the Mycobacterium bovis strain Bacille Calmette Guerin (BCG), which is locally instilled into the bladder, has been shown to induce Th1 CD4+ T cell responses against the tumour, which provide long-term protection against the cancer in mice. The importance of CD4+ T cells in driving anti-tumour responses have been demonstrated in other studies for instance by showing that melanoma-derived neoepitopes are recognized by CD4+ T cells. Further, neoantigen vaccinations in melanoma and IDH1 -specific- as well as designer neoantigen vaccines in glioblastoma primarily activate CD4+ T cells.
[0006] As another promising line of evidence, which hints at a possible involvement of pathogens or commensal bacteria in anti-tumour responses, several types of tumours harbour bacteria. Melanoma metastases even present bacterial peptides on their HLA-class I and -class II molecules indicating that bacterial antigens are available for T cell recognition and thus could be employed for improving tumour vaccination. Intratumoural bacteria may influence tumour outcome positively and negatively in several ways including direct effects on transcriptional pathways influencing inflammation, tumour growth and immune cell infiltration. Regarding anti-tumour immunity, microbiota participate in shaping the adaptive immune repertoire by stimulation via pathogen-associated molecular patterns (PAMPs), by producing immune-modulating metabolites, and, most interestingly in the context of tumour vaccination, by inducing cross-reactive T cell responses.
[0007] Based on the above-mentioned state of the art, the objective of the present invention is to provide means and methods to obtain improved peptides for use in cancer vaccines that effectively break immune tolerance to self-antigens expressed within tumours. This objective is attained by the subject-matter of the independent claims of the present specification, with further advantageous embodiments described in the dependent claims, examples, figures and general description of this specification.
[0008] Summary of the Invention
[0009] The invention relates to bacterial and gut microbiota-derived peptide sequences that stimulate single tumour-infiltrating lymphocyte (TIL)-derived T cell clones, and also bulk TILs and even peripheral blood CD4+ memory T cells, facilitating expansion of a T cell population which can cross-recognize tumour- derived target antigens of glioblastoma. It further relates to T cell clones (TCC) and their TCRs, which had been isolated from the TILs and which recognize >60 bacterial I gut microbiota-derived peptides as well as a target of the tumour (TCC 88) or, for TCC 8F7, >30 mutated and unmutated target antigens of the glioblastoma.
[0010] A first aspect of the invention relates to an isolated peptide for use in treatment or prevention of cancer, or in treatment or prevention of recurrence of cancer, in particular for use as a cancer vaccine, wherein the isolated peptide comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 001 , 002, 003, to SEQ ID NO 063.
[0011] An alternative of this aspect of the invention relates to a bacterial peptide preparation for use in treatment or prevention of cancer, or in treatment or prevention of recurrence of cancer, in particular for use as a cancer vaccine, said preparation comprising at least two, particularly five, ten, fifteen or all of the peptides of the group consisting of SEQ ID NO: 001 , 002, 003, to SEQ ID NO 063.
[0012] A third aspect of the invention relates to an isolated peptide consisting of a sequence selected from the group consisting of SEQ ID NO: 001 , 002, 003, to SEQ ID NO 063.
[0013] Another aspect of the invention relates to a T cell receptor polypeptide comprising a variable alpha chain comprising a CDR3 sequence SEQ ID NO 064, and a variable beta chain comprising a CDR3 sequence SEQ ID NO 065; or a variable alpha chain comprising a CDR3 sequence SEQ ID NO 066, and a variable beta chain comprising a CDR3 sequence SEQ ID NO 067.
[0014] Yet another aspect of the invention relates to nucleic acid sequences and nucleic acid expression vectors encoding one or more peptides an / or TCR polypeptides according to the invention. Likewise, pharmaceutical compositions and methods of treatment making use of the peptides, TCRs and nucleic acids according to the invention are provided.
[0015] Terms and definitions
[0016] For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa. In the event that any definition set forth below conflicts with any document incorporated herein by reference, the definition set forth shall control.
[0017] The terms “comprising,” “having,” “containing,” and “including,” and other similar forms, and grammatical equivalents thereof, as used herein, are intended to be equivalent in meaning and to be open-ended in that an item or items following any one of these words is not meant to be an exhaustive listing of such item or items, or meant to be limited to only the listed item or items. For example, an article “comprising” components A, B, and C can consist of (i.e., contain only) components A, B, and C, or can contain not only components A, B, and C but also one or more other components. As such, it is intended and understood that “comprises” and similar forms thereof, and grammatical equivalents thereof, include disclosure of embodiments of “consisting essentially of’ or “consisting of.”
[0018] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
[0019] Reference to “about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X.”
[0020] "And / or" where used herein is to be taken as specific recitation of each of the two specified features or components with or without the other. Thus, the term "and / or" as used in a phrase such as "A and / or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and / or" as used in a phrase such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0021] As used herein, including in the appended claims, the singular forms “a,” “or,” and “the” include plural referents unless the context clearly dictates otherwise.
[0022] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, nucleic acid chemistry, hybridization techniques and biochemistry). Standard techniques are used for molecular, genetic, and biochemical methods (see generally, Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed. (2012) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Ausubel et al., Short Protocols in Molecular Biology (2002) 5th Ed, John Wiley & Sons, Inc.) and chemical methods. Sequences
[0023] In the context of the present specification, the terms sequence identity and percentage of sequence identity refer to a single quantitative parameter representing the result of a sequence comparison determined by comparing two aligned sequences position by position. Methods for alignment of sequences for comparison are well-known in the art. Alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2:482 (1981), by the global alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman, Proc. Nat. Acad. Sci. 85:2444 (1988) or by computerized implementations of these algorithms, including, but not limited to: CLUSTAL, GAP, BESTFIT, BLAST, FASTA and TFASTA. Software for performing BLAST analyses is publicly available, e.g., through the National Centre for Biotechnology-Information (http: / / blast.ncbi.nlm.nih.gov / ). Reference to identical sequences without specification of a percentage value implies 100% identical sequences (i.e. the same sequence).
[0024] A useful method for comparison of amino acid sequences is the BLASTP algorithm that uses the default settings: Expect threshold: 10; Word size: 3; Max matches in a query range: 0; Matrix: BLOSUM62; Gap Costs: Existence 11 , Extension 1 ; Compositional adjustments: Conditional compositional score matrix adjustment. One such example for comparison of nucleic acid sequences is the BLASTN algorithm that uses the default settings: Expect threshold: 10; Word size: 28; Max matches in a query range: 0; Match / Mismatch Scores: 1 .-2; Gap costs: Linear. Unless stated otherwise, sequence identity values provided herein refer to the value obtained using the BLAST suite of programs (Altschul et al., J. Mol. Biol. 215:403-410 (1990)) using the above identified default parameters for protein and nucleic acid comparison, respectively.
[0025] The term nucleic acid expression vector in the context of the present specification relates to a plasmid, a viral genome or an RNA, which is used to transfect (in case of a plasmid or an RNA) or transduce (in case of a viral genome) a target cell with a certain gene of interest, or -in the case of an RNA construct being transfected- to translate the corresponding protein of interest from a transfected mRNA. For vectors operating on the level of transcription and subsequent translation, the gene of interest is under control of a promoter sequence and the promoter sequence is operational inside the target cell, thus, the gene of interest is transcribed either constitutively or in response to a stimulus or dependent on the cell’s status. In certain embodiments, the viral genome is packaged into a capsid to become a viral vector, which is able to transduce the target cell.
[0026] General Biochemistry: Peptides, Amino Acid Sequences
[0027] The term polypeptide in the context of the present specification relates to a molecule consisting of 50 or more amino acids that form a linear chain wherein the amino acids are connected by peptide bonds. The amino acid sequence of a polypeptide may represent the amino acid sequence of a whole (as found physiologically) protein or fragments thereof. The term "polypeptides" and "protein" are used interchangeably herein and include proteins and fragments thereof. Polypeptides are disclosed herein as amino acid residue sequences. The term peptide in the context of the present specification relates to a molecule consisting of in particular 8 to 30 amino acids that form a linear chain wherein the amino acids are connected by peptide bonds. Peptides of use according to the invention are T cell epitopes, which may bind to, and be presented by, HLA molecules expressed on the surface of cell, particularly a tumour cell or an antigen presenting cell. An internal binding motif called an HLA-binding motif, (also termed a binding register) region of approximately 8-1 1 amino acids within the peptide interacts with T cell receptors in the context of HLA presentation. Peptides binding to HLA allele polypeptides of particular use according to the invention to activate CD4+ and CD8+ T cells are generally 8 to 25 amino acids in length.
[0028] Amino acid residue sequences are given from amino to carboxyl terminus. Capital letters for sequence positions refer to L-amino acids in the one-letter code (Stryer, Biochemistry, 3rded. p. 21). Lower case letters for amino acid sequence positions refer to the corresponding D- or (2R)-amino acids. Sequences are written left to right in the direction from the amino to the carboxy terminus. In accordance with standard nomenclature, amino acid residue sequences are denominated by either a three letter or a single letter code as indicated as follows: Alanine (Ala, A), Arginine (Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cysteine (Cys, C), Glutamine (Gin, Q), Glutamic Acid (Glu, E), Glycine (Gly, G), Histidine (His, H), Isoleucine (He, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F), Proline (Pro, P), Serine (Ser, S), Threonine (Thr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine (Vai, V). Citrulline (Cit) is (2S)-2-amino-5-(carbamoylamino)pentanoic acid (CAS No. 372-75-8).
[0029] Binding, HLA binding, HLA binding peptides
[0030] The term HLA in the context of the present specification relates to the products on the major histocompatibility complex (MHC), in humans known as the human leukocyte antigen (HLA) located on chromosome 6, having the biological role of presenting processed peptide antigens to specifically reactive T cell receptors on T cells. Polymorphic expression of HLA among humans requires molecular HLA typing of patients to be routinely performed in the clinic, for example in transplantation procedures, to identify the specific HLA class I and class II alleles expressed as proteins, inherited in a Mendelian fashion from each parent.
[0031] The term HLA class I allele in the context of the present specification relates to the gene, or gene product of the HLA class I gene family mediating antigen presentation to CD8+ T cells. HLA class I allele HLA- A, HLA-B and HLA-C genes encode glycosylated heavy chains which associate non-covalently with an invariant beta-2-microglobulin chain to provide a membrane bound structure forming a peptide-binding groove between two alpha helices and a beta-pleated floor, to provide a binding site for processed peptide antigen from within the cell. The class I peptide binding groove accommodates peptides 8 to 10, usually 9 amino acids in length.
[0032] The term HLA class II allele in the context of the present specification relates to the genes, or the gene product of the HLA class II gene family, which mediate antigen presentation to CD4+ T cells. The HLA class II alleles DR, DP, and DQ and their subfamilies encode glycosylated alpha and beta heavy chains which associate as heterodimers to form a membrane bound structure creating a peptide-binding groove between the alpha 1 domain and the beta 1 domain, to provide a binding site for exogenously derived peptide antigen. The class II peptide binding groove accommodates longer peptides 8 to 25, usually around 12 amino acids in length, and these longer peptides may comprise one or more 8-11 amino acid HLA-binding motifs with the capacity to bind to an HLA peptide binding groove.
[0033] The term tumour antigen in the context of the present specification relates to a protein expressed by cancer cells present within a tumour. It encompasses both tumour antigens commonly present in certain types of cancers, for example, testis antigens, or proteins which have been detected (either at the level of protein, or at gene expression) in a tumour sample obtained from a cancer patient. Tumour antigens may, or may not comprise a tumour-specific, non-inherited mutation.
[0034] In the context of the present specification, the term "concatenate" refers to the process of combining multiple sequences, particularly DNA, RNA, or protein sequences, end-to-end to form a single, longer sequence.
[0035] Pharmaceutical compositions and treatment of cancer
[0036] The term cancer as used in the context of the present specification relates to malignant neoplastic disease; the terms “cancer” and “malignant neoplastic disease” are used synonymously herein. They specifically include carcinoma (epithelial derived cancer), sarcoma (connective tissue derived cancer), lymphoma and leukemia, germ-cell derived tumours and blastomas. Particular alternatives of any of the aspects and embodiments disclosed herein are directed at the use of the compounds and compositions of the invention in treatment of solid tumours, particularly brain tumours, more particularly glioblastomas. Other alternatives of any of the aspects and embodiments disclosed herein are directed at the use of the combinations of the invention in treatment of liquid cancers such as myelogenous or granulocytic leukemia, particularly AML, lymphatic, lymphocytic, or lymphoblastic leukemia and lymphoma, polycythemia vera or erythremia.
[0037] The term “for use as a cancer vaccine" in the context of this specification relates to the use of the agent thus described in the context of an intervention that aims to elicit an immune response against a neoplastic disease as defined above. Cancer vaccines may be given in the context of other components of a combination medication, for example in addition to checkpoint inhibitor / modulator administration.
[0038] As used herein, the term pharmaceutical composition refers to a peptide or polypeptide as described herein, together with at least one pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition according to the invention is provided in a form suitable for topical, parenteral or injectable administration.
[0039] As used herein, the term pharmaceutically acceptable carrier includes any solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (for example, antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavouring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington: the Science and Practice of Pharmacy, ISBN 0857110624). The invention also encompasses nanoparticles, liposomes, or cellular carriers within the meaning of pharmaceutically acceptable carrier. As used herein, the term treating or treatment of any cancer refers in one embodiment, to ameliorating the disease or disorder (e.g. slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, "treating" or "treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. Methods for assessing treatment and / or prevention of disease are generally known in the art, unless specifically described hereinbelow.
[0040] (Cancer) Immunotherapy
[0041] In the context of the present specification, the term cancer immunotherapy, biological or immunomodulatory therapy is meant to encompass types of cancer treatment that help the immune system to fight cancer. Non-limiting examples of cancer immunotherapy include immune checkpoint inhibitors and agonists, T cell transfer therapy, cytokines and their recombinant derivatives, adjuvants, and vaccination with small molecules or cells.
[0042] In the context of the present specification, the term checkpoint inhibitory agent or checkpoint inhibitor antibody is meant to encompass a cancer immunotherapy agent, particularly an antibody (or antibodylike molecule) capable of disrupting an inhibitory signalling cascade that limits immune cell activation, known in the art as an immune checkpoint mechanism. In certain embodiments, the checkpoint inhibitory agent or checkpoint inhibitor antibody is an antibody to CTLA-4 (Uniprot P16410), PD-1 (Uniprot Q15116), PD-L1 (Uniprot Q9NZQ7), B7H3 (CD276; Uniprot Q5ZPR3), VISTA (Uniprot Q9H7M9), TIGIT (UniprotQ495A1), TIM-3 (HAVCR2, Uniprot Q8TDQ0), CD158 (killer cell immunoglobulin-like receptor family), TGF-beta (P01 137).
[0043] In certain embodiments, the cancer immunotherapy agent is selected from the clinically available antibody drugs ipilimumab (Bristol-Myers Squibb; CAS No. 477202-00-9), nivolumab (Bristol-Myers Squibb; CAS No 946414-94-4), pembrolizumab (Merck Inc.; CAS No. 1374853-91-4), pidilizumab (CAS No. 1036730-42-3), atezolizumab (Roche AG; CAS No. 1380723-44-3), Avelumab (Merck KGaA; CAS No. 1537032-82-8), Durvalumab (Astra Zenaca, CAS No. 1428935-60-7), and Cemiplimab (Sanofi Aventis; CAS No. 1801342-60-8).
[0044] In the context of the present specification, the term checkpoint agonist agent or checkpoint agonist antibody is meant to encompass a cancer immunotherapy agent, particularly but not limited to an antibody (or antibody-like molecule) capable of enhancing an immune cell activation signalling cascade. The term checkpoint agonist agent further encompasses cytokines, recombinant immune stimulatory proteins, vaccines, adjuvants and agonist antibodies that promote immune activation. Non-limiting examples of cytokines known to stimulate immune cell activation include, IL-12, IL-2, IL-15, IL-21 and interferon-alpha. In certain embodiments, the checkpoint agonist agent or checkpoint agonist antibody is an antibody to CD122 (Uniprot P14784) and CD137 (4-1 BB; Uniprot Q07011), ICOS (Uniprot Q9Y6W8), 0X40 (GP34, Uniprot P43489), or CD40 (Uniprot P25942).
[0045] In certain embodiments, the cancer immunotherapy is meant to encompass immune cell transfer cancer treatments wherein a patient’s immune cells are activated or expanded in vitro, and / or genetically modified, for example with the addition of a chimeric antigen receptor, before being infused back into the patient to inhibit neoplastic disease. Non-limiting examples of immune cell transfer therapy include chimeric antigen receptor T lymphocytes, and autologous activated T cells or dendritic cells.
[0046] In the context of the present specification, the term checkpoint inhibitory agent or checkpoint inhibitory antibody is meant to encompass an agent, particularly an antibody (or antibody-like molecule) capable of disrupting the signal cascade leading to T cell inhibition after T cell activation as part of what is known in the art the immune checkpoint mechanism. Non-limiting examples of a checkpoint inhibitory agent or checkpoint inhibitory antibody include antibodies to CTLA-4 (Uniprot P16410) such as exemplified by ipilimumab (Yervoy; CAS No. 477202-00-9), or antibodies to PD-1 (Uniprot Q15116) or to PD-L1 (Uniprot Q9NZQ7), B7H3 (CD276; Uniprot Q5ZPR3), such as exemplified by the clinically available antibody drugs nivolumab (Bristol-Myers Squibb; CAS No 946414-94-4), pembrolizumab (Merck Inc.; CAS No. 1374853-91-4), pidilizumab (CAS No. 1036730-42-3), atezolizumab (Roche AG; CAS No. 1380723-44-3), and Avelumab (Merck KGaA; CAS No. 1537032-82-8).
[0047] In the context of the present specification, the term “adoptive cell therapy” (ACT), also used as adoptive therapy or adoptive T-cell therapy represents a recent immunotherapeutic approach within the realm of cancer treatment, which uses the potent anti-tumour capabilities of autologous (a patient's own) or allogeneic (another patient’s) immune cells by engineering or activating the cells for enhanced tumour recognition and destruction. The process of adoptive cell therapy begins with the extraction of specific immune cells, typically T cells, from a patient's bloodstream; alternatively, the cells may be derived from a cell bank. These cells are then modified ex vivo through genetic engineering techniques or activated ex vivo through various stimulation methods, to enhance their tumour-specific recognition and cytotoxicity. The genetic modification may involve the introduction of chimeric antigen receptors (CARs), which are synthetic receptors designed to target tumour-associated antigens, thus endowing the T cells with precise tumour recognition capabilities. Alternatively, T cell receptor (TOR) genes can be transduced to equip the T cells with the ability to recognize tumour-specific antigens. The engineered or activated T cells are then expanded to generate a substantial population, often referred to as a cell product. Once the cell product is prepared, it is infused into the patient. Adoptive therapy encompasses modalities such as Chimeric Antigen Receptor (CAR) T-Cell Therapy, wherein T cells are genetically engineered to express CARs specific to tumour antigens; Tumor-Infiltrating Lymphocyte (TIL) therapy; T-Cell Receptor (TCR) Therapy, which involves genetically modifying T cells to express TCRs specific for tumour antigens; Natural Killer (NK) Cell Therapy.
[0048] The term “an immunologically cold tumouT in the context of the present specification relates to a tumour against which no sufficient immune response is established by the patient prior to intervention. It encompasses both the absence or, compared to tumours such as melanoma, relative absence of immune cell infiltration in the tumour, but also a low or, compared to tumours such as melanoma, lower number of somatic mutations of the tumour. Detailed Description of the Invention
[0049] Isolated peptides for use as a cancer vaccine
[0050] An aspect of the invention relates to an isolated peptide for use in treatment or prevention of cancer. An alternative of this aspect of the invention relates to an isolated peptide for use in treatment or prevention of recurrence of cancer. The isolated peptide is a short peptide 10 to 15 amino acids in size and comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008, 009, 010, 01 1 , 012, 013, 014, 015, 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026, 027, 028, 029, 030, 031 , 032, 033, 034, 035, 036, 037, 038, 039, 040, 041 , 042, 043, 044, 045, 046, 047, 048, 049, 050, 051 , 052, 053, 054, 055, 056, 057, 058, 059, 060, 061 , 062 and SEQ ID NO 063.
[0051] These peptides were found by the inventors to stimulate TCC88, T cell clone further explored in the Examples herein and subject matter of the current invention also.
[0052] In certain embodiments, the peptide for use in treatment or prevention of recurrence of cancer comprises or consists of a sequence selected from the group of SEQ ID NO 001 , 010, 01 1 , 012, 014, 016, 017, 026, 027, 032, 034, 035, 036, 037, 040, 042, 045, 046, 048, 049, 051 , 052, 053, 055, and SEQ ID NO 060. These peptides were shown in the Examples to stimulate at least one group of T cells analysed, in addition to TCC88, and thus show a broader utility within the samples available to the inventors.
[0053] In more particular embodiments, the peptide for use in treatment or prevention of recurrence of cancer comprises or consists of a sequence selected from the group of SEQ ID NO 001 and 032.
[0054] SEQ ID NO 001 and 032 were found in the Examples to be stimulatory for bulk TIL, other TCC of the same patient and bulk TIL from a second patient.
[0055] In particular embodiments, the peptide is a dodecapeptide comprising one of the indicated sequences.
[0056] In more particular embodiments, the peptide is a decapeptide matching one of the indicated sequences.
[0057] In a particular embodiment, the peptide is provided for use as a cancer vaccine, more particularly as a vaccine to treat a brain tumour, or prevent recurrence of such brain tumour. In an even more particular embodiment, the peptide is provided for use in treatment or prevention of recurrence of glioma. In an even more particular embodiment, the peptide is provided for use in treatment or prevention of recurrence of glioblastoma (GBM).
[0058] Peptide preparations comprising two and more peptides for use as a cancer vaccine
[0059] Another aspect of the invention relates to a preparation of isolated bacterial peptides for use in treatment or prevention of cancer. This preparation comprises at least two peptides selected from the group consisting of SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008, 009, 010, 01 1 , 012, 013, 014, 015,
[0060] 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026, 027, 028, 029, 030, 031 , 032, 033, 034, 035,
[0061] 036, 037, 038, 039, 040, 041 , 042, 043, 044, 045, 046, 047, 048, 049, 050, 051 , 052, 053, 054, 055,
[0062] 056, 057, 058, 059, 060, 061 , 062 and SEQ ID NO 063. In an embodiment, the preparation of isolated bacterial peptides for use in treatment or prevention of cancer comprises SEQ ID NO 001 and 032.
[0063] In an embodiment, the preparation of isolated bacterial peptides for use in treatment or prevention of cancer comprises at least five, particularly 10 or even more particularly fifteen of SEQ ID NO 001 , 010, 011 , 012, 014, 016, 017, 026, 027, 032, 034, 035, 036, 037, 040, 042, 045, 046, 048, 049, 051 , 052, 053, 055, 060. In an embodiment, the preparation of isolated bacterial peptides for use in treatment or prevention of cancer comprises all of SEQ ID NO 001 , 010, 01 1 , 012, 014, 016, 017, 026, 027, 032, 034, 035, 036, 037, 040, 042, 045, 046, 048, 049, 051 , 052, 053, 055, and SEQ ID NO 060.
[0064] In an embodiment, the preparation of isolated bacterial peptides for use in treatment or prevention of cancer comprises at least five, particularly 10 or even more particularly fifteen of SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008, 009, 010, 01 1 , 012, 013, 014, 015, 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026, 027, 028, 029, 030, 031 , 032, 033, 034, 035, 036, 037, 038, 039, 040, 041 , 042, 043, 044, 045, 046, 047, 048, 049, 050, 051 , 052, 053, 054, 055, 056, 057, 058, 059, 060, 061 , 062 and SEQ ID NO 063. In an embodiment, the preparation of isolated bacterial peptides for use in treatment or prevention of cancer comprises all of SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008, 009, 010, 011 , 012, 013, 014, 015, 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026, 027, 028, 029, 030, 031 , 032, 033, 034, 035, 036, 037, 038, 039, 040, 041 , 042, 043, 044, 045, 046, 047, 048, 049, 050, 051 , 052, 053, 054, 055, 056, 057, 058, 059, 060, 061 , 062 and SEQ ID NO 063.
[0065] One particular embodiment encompasses the use of the preparation of isolated bacterial peptides as a cancer vaccine. In more particular embodiments, the preparation of isolated bacterial peptides is used as a vaccine to treat or prevent recurrence of brain cancer, yet more particularly glioma or glioblastoma.
[0066] In an alternative of this aspect of the invention, the peptide is not delivered as an oligomer of the proteinogenic amino acids, but encoded as a polynucleotide sequence under control of a suitable regulatory sequence. An mRNA or DNA encoding a peptide, a plurality of peptides or a preparation according to the invention can equally well be used for vaccination. The recent development of vaccines against SarsCoV-2 has demonstrated the power and efficacy of mRNA delivery.
[0067] Similarly, a combination of the peptides provided herein may not be administered as individual peptides, encoded by nucleic acid or administered in peptide form, but as concatenates wherein individual peptides are joined by short linkers, to create an oligopeptide or polypeptide containing multiple decapeptide sequences as provided herein for stimulating tumour-infiltrating lymphocytes, which can be used for adoptive immunotherapy. A nucleic acid encoding such concatenate, or a viral vector or bacterium expressing such concatenate of multiple peptides as provide herein may serve as a vaccinating vehicle.
[0068] In certain embodiments the peptide linker is <4 amino acids in length, particularly 2 or 3 amino acids in length wherein the amino acids are selected from G, S, and A.
[0069] A non-limiting example of an amino acid linker is a monomer of a dipeptide or tripeptide motif composed of two or three glycine and optionally, one serine. Combinations of peptides or peptide preparations with cancer immunotherapy
[0070] Another aspect of the invention relates to a combination of an isolated peptide as provided above, or of a bacterial peptide preparation as provided above, together with a cancer immunotherapy agent.
[0071] Reactivity to anti-CTLA-4 intervention has been associated with presence of certain gut microbiota (Vetizou et al., Science 2015, 350(6264): 1079-1084) and the results presented herein suggest that an anti-tumour immune response generated by peptide epitopes of the invention pairs with immune checkpoint blockers such as anti-CTLA-4 antibodies, anti-PD-1 antibodies or anti PD-L1 antibodies.
[0072] In certain embodiments, the peptide or peptide preparation is administered in combination with administration of a checkpoint inhibitor / modulator. The peptide or peptide preparation may be administered prior to, concomitant with, or subsequent to, administration of a checkpoint inhibitor / modulator.
[0073] Alternatively, this aspect of the invention may be regarded as the provision of a checkpoint inhibitor / modulator in combination with a peptide or peptide combination as provided herein, for use in treatment or prevention of recurrence of cancer.
[0074] In certain particular embodiments, the checkpoint inhibitor / modulator is administered subsequent to, concomitant with, or prior to, administration of the peptide or peptide preparation according to the invention.
[0075] Combinations of peptides or peptide preparations with adoptive T cell therapy
[0076] Another aspect of the invention relates to a combination of an isolated peptide as provided above, or of a bacterial peptide preparation as provided above, together with an adoptive T cell therapy.
[0077] The peptides of the invention have shown to stimulate certain T cells, particularly T cell clones characterized by T cell receptors provided herein. Administration of these peptides and peptide preparations together with adoptive transfer of cells bearing these T cell receptors, or with agents incorporating the T cell receptor sequences in a soluble format (multivalent chimeric immunomodulators; see Dolgin, Nature Biotechnology 40 (202), 441-449; and Robinson et al, The FEBS Journal 288 (2021) 6159-6173) is expected to potentiate their effect.
[0078] In a particular embodiment, the peptide or peptide preparation is administered prior to, concomitant with, or subsequent to, administration of a T cell preparation expressing a transgene encoding a T cell receptor polypeptide comprising: a) a CDR3 sequence SEQ ID NO 064 and a CDR3 sequence SEQ ID NO 065; or b) a CDR3 sequence SEQ ID NO 066 and a CDR3 sequence SEQ ID NO 067.
[0079] Isolated peptides (compound protection)
[0080] Another aspect of the invention provides an isolated decapeptide selected from SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008, 009, 010, 011 , 012, 013, 014, 015, 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026, 027, 028, 029, 030, 031 , 032, 033, 034, 035, 036, 037, 038, 039, 040, 041 , 042, 043, 044, 045, 046, 047, 048, 049, 050, 051 , 052, 053, 054, 055, 056, 057, 058, 059, 060, 061 , 062, and SEQ ID NO 063.
[0081] None of the peptides are known as isolated decamer sequence in any of the databases consulted by the inventors.
[0082] In a particular embodiment, the peptide comprises or consists of a sequence selected from the group of 001 , 010, 011 , 012, 014, 016, 017, 026, 027, 032, 034, 035, 036, 037, 040, 042, 045, 046, 048, 049, 051 , 052, 053, 055, and SEQ ID NO 060.
[0083] In a more particular embodiment, the peptide selected from the group of SEQ ID NO 001 and 032.
[0084] An oligopeptide as provided herein may be used for administration as a vaccine alone or in combination with other peptides or TOR polypeptides in different forms: the N terminus may be an amine -NH2 (protonated depending on pH to NHs+), or may be acetylated. The C terminus may be a carboxylic acid COOH (deprotonated depending on pH to COO ), or may be amidated. Other modifications to increase stability are known to the skilled artisan (see Yao et al, Curr Drug Metab 2018;19(11):892-901) Furthermore, one could introduce positively- or negatively charged amino acids at the ends to increase solubility, and another interesting modification at the ends could the introduction of a D-amino acid to prolong the in vivo half-life.
[0085] Another aspect of the invention relates to a nucleic acid expression vector encoding peptide characterised by a sequence selected from SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008, 009, 010, 011 , 012, 013, 014, 015, 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026, 027, 028, 029,
[0086] 030, 031 , 032, 033, 034, 035, 036, 037, 038, 039, 040, 041 , 042, 043, 044, 045, 046, 047, 048, 049,
[0087] 050, 051 , 052, 053, 054, 055, 056, 057, 058, 059, 060, 061 , 062, and SEQ ID NO 063.
[0088] T cell receptor polypeptides, nucleic acids encoding, and transgenic cells expressing TCR
[0089] Another aspect of the invention relates to a T cell receptor polypeptide comprising a variable alpha chain comprising a CDR3 sequence SEQ ID NO 064, and a variable beta chain comprising a CDR3 sequence SEQ ID NO 065.
[0090] TCC88 (CDR3 alpha sequence SEQ ID NO 064, and a beta chain comprising a CDR3 sequence SEQ ID NO 065) is restricted by HLA-DRB3*02:02.
[0091] Alternatively, a T cell receptor polypeptide according to the invention comprises a variable alpha chain comprising a CDR3 sequence SEQ ID NO 066, and a variable beta chain comprising a CDR3 sequence SEQ ID NO 067.
[0092] TCC8F7 (CDR3 alpha sequence SEQ ID NO 066, and a beta chain comprising a CDR3 sequence SEQ ID NO 067) is restricted by HLA-DRB1 *03:01 .
[0093] The inventors have observed previously that single T cell clones and their TCRs are capable of recognizing their target antigen in the context of more than one restriction element (Sospedra et al., J. Immunol., 176: 1951-1956 (2006); Wang et al. Cell 183(5):1264-1281 (2020)). One illustrative example is the fact that TCC88 recognizes the SIN3A peptide in the context of DRB3*02:02, but at least three more of the autologous HLA-DR molecules (see the Examples of the present specification). Hence, this phenomenon, which the inventors refer to as cross-restriction (as opposed to crossreactivity, which refers to the ability to recognize multiple peptides) is more frequent than often recognized in the art. Given the low affinity of TOR - HLA / peptide interactions in the lower micromolar range, the finding fits biophysical theory of binding, but as the expectation of many practitioners appears to be that a) every T cell is very specific and recognizes only one or a few antigens, and b) every T cell uses only one HLA-class I or -II restriction element, it is not well recognized.
[0094] Adaptations of the CDR2 regions - while in principle possible - are not necessary, since the TOR clones provided herein do already use multiple restriction elements (TCC88 is reactive to DRB1 *0301 , DRB1*0402, DRB4*0101.
[0095] CDR regions can be identified according to convention by means of various online tools such as:
[0096] MiTCR https: / / www.nature.com / articles / nmeth.2555 (Bolotin et al., Nature Methods 10, p.813-814 (2013))
[0097] MiXCR https: / / www.nature.com / articles / nmeth.3364 (Bolotin et al., Nature Methods 12, pages 380-381 (2015))
[0098] Immcantation https: / / immcantation.readthedocs.io / en / stable / index.html
[0099] The T cell receptor sequences as provided herein are of high interest in the context of their use tumour therapy, because they recognize multiple antigens and can use multiple restriction elements, i.e. they are both cross-reactive and also cross-restricted (TOO 88) or highly cross-reactive against multiple tumour antigens (TOO 8F7). Thus, the invention provides the T cell receptor polypeptides disclosed herein for use in treatment or prevention of recurrence of cancer. In a particular embodiment, the T cell receptor polypeptides disclosed herein are provided for use as a cancer vaccine, more particularly as a vaccine to treat a brain tumour, or prevent recurrence of such brain tumour. In an even more particular embodiment, the T cell receptor polypeptides disclosed herein are provided for use in treatment or prevention of recurrence of glioma, more particularly, for use in treatment or prevention of recurrence of glioblastoma (GBM).
[0100] With respect to their potential uses, the following exemplary (and non-exclusive) applications for the TOR polypeptides as disclosed herein are provided:
[0101] A bulk population of cytotoxic T cells or a single cytotoxic T cell clone may be genetically manipulated to express a transgene or transgenes encoding a TOR, which will endow the transduced T cells with the ability to recognize multiple tumour targets and in the context of more than one HLA-class II restriction element and kill the tumour cell, particularly when administered in combination with a peptide as provided herein.
[0102] Similarly, a bi-specific, chimeric construct may be used, which combines a recombinant TOR polypeptide as provided herein, together with a second immunomodulatory moiety interacting with an effector or modulator cell of the immune system. Examples of second immunomodulatory moieties are antibody fragments binding to CD3, CD4 or CD8.
[0103] Soluble T cell receptor applications have recently enjoyed significant scientific and commercial attention. Reviews on formats include Robinson et al, The FEBS Journal 288 (2021) 6159-6173, and Dolgin, Nature Biotechnology 40, 441-444 (2022). The TCR polypeptides and nucleic acid vaccines encoding same of the current invention offer themselves for such soluble formats.
[0104] The two TCRs are both of interest for potential CAR-T, bi-specific TCR / antibody ligand or adoptive therapies. The recognition displayed by both TCC88 and TCC8F7 of multiple peptides, often belonging to the same organism or protein, demonstrates that these clones have rather broad cross-reactivity, but at the same time, this cross-reactivity is directed at antigens that share commonalities, which are important in the respective biological context. These TCRs appear to belong to presumably rare group of TCR that are capable of recognizing a larger number of peptides, both from self- and non-self sources (See Hemmer et al., Nature Medicine volume 5, pages 1375-1382 (1999); Jelcic et al., Cell 175, 85- 100 (2018); Wang et al. 2020, Cell 183, 1-18).
[0105] Another aspect of the invention relates to a nucleic acid expression vector encoding a T cell receptor polypeptide comprising a variable alpha chain comprising a CDR3 sequence SEQ ID NO 064, and a variable beta chain comprising a CDR3 sequence SEQ ID NO 065, or a T cell receptor polypeptide comprising a variable alpha chain comprising a CDR3 sequence SEQ ID NO 066, and a variable beta chain comprising a CDR3 sequence SEQ ID NO 067.
[0106] In a particular embodiment, this nucleic acid expression vector is provided for use in treatment or prevention of recurrence of cancer, in particular for use as a cancer vaccine. In another particular embodiment, the nucleic acid expression vector encoding T cell receptor polypeptides disclosed herein is provided for use as a cancer vaccine, more particularly as a vaccine to treat a brain tumour, or prevent recurrence of such brain tumour. In an even more particular embodiment, the nucleic acid expression vector is provided for use in treatment or prevention of recurrence of glioma, more particularly, for use in treatment or prevention of recurrence of glioblastoma (GBM).
[0107] Likewise, the invention relates to a pharmaceutical composition for use in treatment or prevention of cancer. This pharmaceutical composition comprises a peptide characterised by a sequence specified in claim 1 , and / or the T cell receptor polypeptide as specified in claim 6, or the nucleic acid expression vector according to claim 7,
[0108] In certain embodiments of any aspect of the invention directed at treatment or prevention of recurrence of cancer, the cancer is an immunologically cold tumour. As further set forth in the Examples, a particularly advantageous aspect of the invention is the ability of the peptides and TCR polypeptides provided herein to induce an immune reaction against a tumour where prior to the administration of the agent of the invention, such immune reaction was absent.
[0109] In certain particular embodiments, the cancer is selected from a list consisting of pancreatic cancer, prostate cancer, neuroblastoma, or glioma. In more particular embodiments, the cancer is glioblastoma. Method of Manufacture and Method of Treatment according to the invention
[0110] The invention further encompasses, as an additional aspect, the use of a peptide, composition or nucleic acid as specified in detail above, for use in a method of manufacture of a medicament for the treatment or prevention of cancer.
[0111] Similarly, the invention encompasses methods of treatment of a patient having been diagnosed with a cancer. This method entails administering to the patient an effective amount of a peptide, composition or nucleic acid as specified in detail above,
[0112] Wherever alternatives for single separable features are laid out herein as “embodiments”, it is to be understood that such alternatives may be combined freely to form discrete embodiments of the invention disclosed herein.
[0113] The invention is further illustrated by the following Examples and Figures, from which further embodiments and advantages can be drawn. These examples are meant to illustrate the invention but not to limit its scope.
[0114] Description of the Figures
[0115] Fig. 1 : Elution of HLA-ll-presented bacterial / microbial peptides from 19 glioblastomas and examining the stimulatory effect of immunopeptidome-derived bacterial peptides (IPdBPs) on bulk TILs (1635WI). a, 1 . Schematic description of immunopeptidome analyses of glioblastoma tissue, from which eluted peptides were annotated using the UniProt bacteria database. 2, 3. TILs or peripheral memory T cells were stimulated with IPdBPs. b, (I) Number of unique IPdBPs from primary or recurrent tumors of glioblastoma patients (n=19) (data from patient 1635WI contains both primary and recurrent tumors together). 344 unique IPdBPs were identified. These peptides originated from 255 and 199 unique proteins and bacteria, respectively. See also Supplementary Tables 3, 4, 8. (II) Taxonomy of these bacteria shows that they primarily stem from Proteobacteria and Firmicutes at the phylum level while Enterobacteriaceae and Bacillaceae are the most prevalent families, c, (I) IPdBPs from primary and recurrent tumors (1635WI). As a control for the entire experiment, peptidome data were also annotated using human protein database to identify eluted self-peptides. As shown, most of HLA-ll-bound peptides are self-(human) peptides. (II) IPdBPs of primary and recurrent tumors were separately annotated to their source bacteria at the phylum level, d, Bulk tumor-infiltrating lymphocytes isolated from the recurrent tumor (1635WI) were stimulated with 37 unique IPdBPs (See Supplementary Table 8), each in 5 replicate wells and proliferation measured after 5 days via3H-thymidine incorporation. Proliferation is shown with stimulatory index (SI), and peptides with SI > 2 are considered stimulatory (the dotted line shows Sl=2 throughout the paper). The data are expressed as mean value of all wells ± SEM. SIN3A* peptide was used as a positive control since TILs recognize this tumor antigen strongly. Co-culture of T cells with APCs without any stimuli was used as negative control, e, Heatmap of cytokine / chemokine secretion of bulk TILs stimulated with three IPdBPs, which very weakly stimulated proliferation. The secretion of each cytokine / chemokine (pg / ml) was calculated by subtracting the corresponding cytokine / chemokine amount (pg / ml) of the negative control. Co-culture of TILs with APCs without any stimuli was used as negative control. Fig. 2 : Isolation and characterization of tumor-specific TCCs by stimulating TILs with SIN3A* peptide, a, Bulk TILs were CFSE-labeled and stimulated with irradiated autologous PBMCs as APCs pulsed with SIN3A* peptide. After 10 days, 60 replicate wells were pooled and CFSEdimCD3+CD4+T cells were single-cell sorted and expanded using PHA and h-IL-2. b, All isolated TCCs were tested against the cognate antigen (SIN3A* peptide) for proliferation and IFN-y production. After 3 days, proliferation was measured using3H-thymidine incorporation (Sis), and ELISA was used to measure IFN-y secretion. Response of each TCC was compared to the stimulation of the same TCC with APCs without peptide, c, TCRB V- and J- genes and functional phenotypes of several of the TCCs. d, Several TIL-derived TCCs with reactivity to tumor antigen (SIN3A*) were tested for reactivity against IPdBPs. TCCs were stimulated with peptides and irradiated PBMCS as APCs for 3 days. Proliferation was measured using3H-thymidine incorporation. SIN3A* peptide served as positive control. Mean Sis are shown in a heatmap format. Sis lower than 2 (non-stimulatory) were shown with an empty field and only SI > 2 for stimulatory peptides.
[0116] Fig. 3 : Bacteria / microbiota-derived peptides can stimulate TCC88 as well as the tumor antigen, a, Peptides with the highest predicted stimulatory scores were identified by searching various databases (see materials and methods). Numbers of unique 10-mer peptides within each of the databases as well as numbers of synthesized peptides are shown. Moreover, the number of synthesized peptides, which stimulated TCC88, and the corresponding percentage of stimulatory peptides within each database are shown. Proliferation was measured using3H-thymidine incorporation (see Supplementary Table 10). b, TCC88 was stimulated with bacteria / microbiota-derived peptides for 3 days and proliferation measured by3H-thymidine incorporation (data represents mean SI value of 2 replicate wells). “HB” peptides represent UniProt bacteria database and “HGM” peptides represent human gut microbiota (Almeida, A. et al. Nat Biotechnol 39, 105-114 (2021)). c, Pie chart displaying the number of peptides from all databases that stimulated TCC88 equally well or better than the cognate antigen (SIN3A* tumor antigen) at the concentration 10 pM. d, TCC88 was tested with several strongly stimulatory bacteria / microbiota- derived and SIN3A* peptides at decreasing concentrations including 20, 2, 0.2, 0.02 and 0.002 pM. Irradiated BLS-DRB3*02:02 were pulsed with the peptides and used to stimulate TCC88 (data represent mean SI value of 5 replicate wells ±SEM). e, Supernatants were collected from TCC88 after stimulation with SIN3A*, HGM3 and HB84 peptides. Cytokine / chemokine secretion of TCC88 was examined and compared upon stimulation with these 3 different antigens. Specific amount of each cytokine / chemokine (pg / ml) was calculated by subtracting the cytokines in the negative control cultures (no peptide control), f, Cytotoxicity of TCC88 against autologous tumor cell line after stimulation with 2 pM of SIN3A*and HGM3 (data represents mean percentage of 2 replicate wells), g, TCC88 was tested with HGM3 (10 pM), SIN3A* (10 pM) peptides or both together (each 10 pM) and3H-thymidine incorporation was measured after 3 days (data represents mean SI value of 3 replicate wells ± SEM).
[0117] Fig. 4: Response of bulk TILs to bacteria / microbiota-derived peptides, a, Bulk TILs were stimulated with bacteria / microbiota-derived peptides and irradiated autologous PBMCs as APCs. Proliferation was measured by3H-thymidine incorporation after 5 days (data represents mean value of 5 replicate wells ± SEM). b, Several TIL-derived TCCs were stimulated with bacteria / microbiota-derived peptides and irradiated autologous PBMCs as APCs. Proliferation was measured by3H-thymidine incorporation after 3 days (data represents mean value of 2 replicate wells), c, Overview of proliferative responses of several TCCs and bulk TILs to bacteria / microbiota-derived peptides shown in a heatmap. SI < 2 are shown with white and SI > 2 are shown in varying shades of grey, d, Supernatants were collected after stimulation of TCC75 with SIN3A* and HGM27 peptides for 3 days. Cytokine / chemokine secretion of TCC75 was examined for the different antigens and depicted in a heatmap.
[0118] Fig. 5: Reactivity of bulk TILs to bacteria / microbiota peptides and tumor antigens, a, Bulk TILs were CFSE-labeled and separately stimulated with a pool of bacteria / microbiota-derived peptides and a pool of vaccine / tumor peptides that includes peptides from somatic mutations and genes that were overexpressed in the autologous tumor (see Supplementary Table 13). Peptide-pulsed, irradiated autologous PBMCs were used as APCs and bulk TILs incubated for 10 days. 60 replicate wells were pooled and proliferating CD4+T cells (CFSEdim) sorted, b, Part of the CFSEdimCD4+TILs that responded to bacteria / microbiota-derived peptide pool was short-term expanded. These cells were stimulated with several tumor antigens from the autologous tumor, bacteria / microbiota-derived peptide pool and a pool of vaccine peptides and irradiated autologous PBMCs as APCs. After 5 days, supernatants were harvested and proliferation measured using3H-thymidine incorporation (data represents mean SI value of 4 replicate wells ± SEM). GM-CSF was measured by ELISA and is depicted in (pg / ml) after subtraction of the negative control, c, Supernatants were tested for secretion of a broader range of cytokines / chemokines. Cytokine / chemokine secretion of bacteria / microbiota-reactive TILs was measured after stimulation with vaccine and bacteria / microbiota-derived peptide pools. Concentrations of cytokines are depicted in (pg / ml) after subtraction of the negative control, d, Part of the CFSEdimCD4+TILs that responded to bacteria / microbiota- and vaccine peptide pools were used for TCRVp sequencing. Percentage and frequency of TCR overlap of unique productive TCRVp sequences of CFSEdimTILs responding to vaccine peptide pool and TCRVp sequences of CFSEdimTILs responding to bacteria / microbiota-derived peptide pool is shown, e, TCR sequence overlap of cross-reactive T cells in TILs recognizing both vaccine- and bacteria / microbiota-derived peptide pools comprise 1 % of entire TILs.
[0119] Fig. 6: Peripheral memory T cells recognize several tumor antigens after activation with bacteria / microbiota-derived peptides, a, CD45RA- peripheral T cells were isolated and CFSE-labeled. Cells were then stimulated with bacteria / microbiota-derived peptide pool for 10 days. Next, 60 replicate wells were pooled and proliferative (CFSEdim) CD4+T cells were sorted and short-term expanded, b, (Top) Bacteria / microbiota-reactive peripheral CD4+T cells responded to several tumor antigens from the autologous tumor when stimulated with peptide presented by irradiated autologous PBMCs as APCs. Proliferation was measured after 5 days by3H-thymidine incorporation (data represent means of 5 replicate wells ± SEM). (Bottom) Peripheral blood memory T cells were isolated and directly tested with tumor antigens. Proliferation was measured after 5 days by3H-thymidine incorporation (data represent means of 5 replicate wells ± SEM). c, Supernatants from the previous experiment were used to measure cytokine / chemokine secretion of bacteria / microbiota-reactive peripheral CD4+T cells (selected peripheral CD4+) and CD45RA- peripheral T cells (unselected peripheral CD4+) in response to a tumor antigen (LRP6). Values (pg / ml) of each molecule were subtracted from its corresponding molecule in the negative control for each group, d-e, Part of CFSEdim(i.e. proliferating) peripheral CD4+ T cells that responded to bacteria / microbiota-derived peptide pool was used for TCRVp sequencing. Percentage and frequency of TCR overlap of unique productive TCRVp sequences of bacteria / microbiota-reactive peripheral CD4+(CFSEdim) and TCRVp sequences of bulk TILs (d), overlap of unique productive TCRVp sequences of bacteria / microbiota-reactive peripheral CD4+(CFSEdim) and TCRVp sequences of (CFSEdim) bacteria / microbiota-reactive TILs (e).
[0120] Examples
[0121] In the experiments performed leading up to the present invention, we pursued several experimental paths to address if and how microbial antigens may contribute to immune reactivity against glioblastoma. We first examined the glioblastoma immunopeptidomes of 19 patients for HLA-ll-bound bacterial peptides, and next whether tumour-infiltrating lymphocytes (TILs) and TIL-derived CD4+ TCCs in one of the patients react against HLA-bound bacterial peptides and tumour antigens. We then used an unbiased antigen discovery approach to identify targets derived from viruses, bacteria, and bacterial gut microbiota, which will be referred to as gut microbiota from now on. TCC88, which is directed against a glioblastoma neoantigen, not only recognizes multiple other glioblastoma-derived peptides, but also responds strongly to a broad spectrum of bacterial- and gut microbiota-derived targets, which also elicit cross-reactive T cell responses against tumour targets in bulk TILs and also peripheral blood memory T cells.
[0122] Example 1: Microbial peptides in HLA-II immunopeptidomes of glioblastoma
[0123] Nejman et al. reported that various tumors contain distinct microbial communities including glioblastoma (Nejman, D. et al. Science 368, 973-980 (2020)). Furthermore and strongly supporting that bacterial antigens within tumors could in principle elicit intra-tumoral immune responses, Kalaora et al. demonstrated that bacterial peptides are found in the HLA-II immunopeptidome of melanoma cells (Kalaora, S. et al. Nature 592, 138-143 (2021)). Although it appears easier that bacterial peptides can get access to and be presented by tumor cells or local antigen presenting cells (APCs) in the skin, we examined whether bacterial peptides also play a role in immune responses against glioblastoma. For this purpose, we first examined the HLA class I- and HLA-ll-associated immunopeptidomes of 19 primary or recurrent glioblastomas and annotated these not only for human proteins and tumor-specific antigens (TSAs, i.e. mutated tumor antigens), but also for sequences from bacteria (UniProtKB / Swiss- Prot protein database) and viruses with tropism for humans (Swiss-Prot-20210305) (Fig. 1a). Interestingly, we identified not only multiple tumor-associated antigens (TAAs), i.e. self-proteins overexpressed in the tumor, and TSAs on both HLA class I and -II molecules (data not shown), but furthermore between 5 to 54 unique HLA-ll-bound bacterial sequences per patient and tumor, but no viral peptides (Fig. 1 bl). As controls, we analyzed the immunopeptidomes from brain lesions of multiple sclerosis (MS) patients and healthy brain tissue (dataset identifier PXD019643). We identified 10 and 45 bacterial hits from the brain tissues of 3 MS patients and 6 healthy donors, respectively. 7 peptides from the control cohorts were exact matches of peptides in GBM samples, and we therefore subtracted these from the bacterial peptides in GBM. Tumor-derived bacterial peptides originated from 255 bacterial proteins and 199 unique bacteria mainly from the phyla Proteobacteria and Firmicutes with Enterobacteriaceae, Bacillaceae and Mycobacteriaceae among the top bacterial families from each phylum (Fig. 1 bll). Composition and number of bacterial peptides differed between patients, although several patients shared HLA alleles. Furthermore, we isolated tumor cell lines from 6 of these patients and analyzed their immunopeptidomes. Interestingly, the tumor cell lines presented similar numbers of HLA- Il-bound bacterial peptides, which will be referred to as immunopeptidome-derived bacterial peptides (IPdBP) from now on. The latter observation indicates that bacterial peptides exist in the tumor cells, are processed and loaded onto HLA molecules and form part of the IPdBPs. However, the number of IPdBPs of both tumor tissue and cell lines was low. Also, both tumor and isolated cell lines showed normal expression of HLA-II in patient 1635WI. We can therefore not rule out the possibility that at least part of the IPdBPs are presented by APCs in the tumor microenvironment. We further conducted 16S rRNA gene sequencing on fresh frozen tumor tissues of 10 GBM patients. Similar to immunopeptidome analyses, bacterial loads in the tumor tissues were low and Proteobacteria accounted for the majority of bacteria in tumors. The 16S rRNA results were then compared to bacterial sources of the IPdBPs in each patient. We found at least one exact match for bacterial species in 5 out of 10 patients. Since the resolution to the level of species is limited due to high similarities of 16S rRNA sequences between certain bacteria, we examined the data at the next taxonomic level, bacterial genus, and found matches in 7 patients. These data suggest the presence of both bacterial DNA as well as peptides in glioblastoma. Next, we assessed the possible immune recognition of IPdBPs in detail in patient 1635WI, whom we had previously treated with a personalized peptide vaccination and checkpoint inhibitors in addition to standard therapy. We identified 18 and 23 unique IPdBPs from the primary and recurrent tumor, respectively (Fig. 1cl), and four in both tumors. Peptides of the primary and recurrent tumor derived from 15 and 21 bacterial proteins. Consistent with the immunopeptidome data of the entire group of patients, Proteobacteria and Firmicutes were the most common phyla (Fig. 1 ell) . Further, we compared the deduced core binding motifs and HLA-DR anchor positions between bacterial and self / tumor peptides within this patient. The amino acid preference at anchor positions of several HLA-DRs of the patient was similar between bacterial and self / tumor peptides, but differed at non-anchor positions.
[0124] Furthermore, we wanted to know whether IPdBPs are involved in the intratumoural immune response by testing the response of bulk TILs from the recurrent glioblastoma (1635WI) with all 37 unique IPdBPs. In comparison to a tumor neoantigen derived from the paired amphipathic helix protein SIN3A, peptide SINA3A* 300-312 (QPVEFNHAIHYVN (SEQ ID NO 070) marks all mutated proteins throughout the paper), which was part of the tumor vaccine, the proliferative response of TILs to the 37 IPdBPs was very weak (Fig. 1d), however, they secreted proinflammatory cytokines including IFN-y, TNF-a and GM- CSF upon stimulation with several of the IPdBPs (Fig. 1e).
[0125] Example 2: Tumor-reactive CD4+T cell clones
[0126] The above data indicate that bacteria-derived peptides may be involved in intratumoural immune responses. Since bulk TIL responses to IPdBPs were weak, we isolated TCCs from the TILs that recognize a tumor antigen with the goal of testing them for possible recognition of IPdBPs. Based on the response of bulk TILs to a strongly stimulatory peptide from the personalized vaccine cocktail (Wang, J. et al. Clin Cancer Res CCR-22-1741 (2022)), an exemplary peptide, SIN3A*, was used to stimulate bulk TILs (Fig. 2a). TCCs were generated from the proliferating CD4+(CFSEdim) T cells (Fig. 2a). 70 out of 127 CD4+TCCs responded to the SIN3A* peptide by proliferation or IFN-y production (Fig. 2b). TCCs were further characterized forTCR expression and functional phenotypes. Most showed a polyfunctional Th1 / Th2 phenotype with production of IFN-y, IL-5 and IL-13 after stimulation via anti-CD2 / CD3 / CD28 antibodies (Fig. 2c). Next, we tested several of these tumor-reactive TCCs with IPdBPs. TCC57 and TCC-2D3 responded to one and several IPdBPs, however, again relatively weakly compared to the SIN3A* peptide (Fig. 2d).
[0127] Example 3: CD4+TCCs cross-recognize microbial peptides
[0128] We next approached the recognition of foreign antigens by intratumoral lymphocytes from a different angle, that is not starting from the immunopeptidome, but with an unbiased antigen discovery methodology, which we had previously used to identify the target epitopes for autoreactive TCCs from the peripheral blood, cerebrospinal fluid (CSF) and brain tissue of multiple sclerosis (MS) patients, and in viral and bacterial infections. It involves testing TCCs with synthetic combinatorial peptides libraries in the positional scanning format (ps-SCL). Individual ps-SCL mixtures are characterized by one defined amino acid in a determined position of a decamer, e.g. L-alanine in position 1 , while the remaining 9 positions are randomized. As a preparatory step for unbiased antigen discovery, we characterized the HLA-DR restriction of several TCCs using irradiated EBV-transformed bare lymphocyte syndrome (BLS) B cells, which had been transfected with single HLA-DR molecules of the patient including DRB1*03:01 , DRB1 *04:02, DRB3*02:02 or DRB4*01 :01. Most CD4+TCCs robustly recognized the SIN3A* peptide when presented by HLA-DRB3*02:02. As previously shown for virus- and autoantigen-specific TCCs, TCC88 showed cross-restriction by responding to the cognate peptide presented on all four HLA-DR molecules but responded strongest to SIN3A* / HLA-DRB3*02:02 (EC50 = 0.013 pM). After testing a TCC with the 200 ps-SCLs, which are presented by BLS cells carrying its restriction element, the experimental data (proliferation or cytokine release) is transformed into a scoring matrix that depicts the stimulatory score for each L-amino acid in each position of a decamer peptide. Based on the assumption that each amino acid contributes independently and additively to T cell recognition, the scoring matrix and a dedicated search algorithm allow scanning any database in order to identify target peptides for the respective TCC in an unbiased way. Peptides with predicted high stimulatory scores, for example with higher than 80% of the maximal score, are then selected, synthesized and tested for recognition by the TCC. We had demonstrated previously for virus-, bacteria-specific and autoreactive TCCs, that there is a strong relation between predicted stimulatory score and recognition by the TCC. Among the above SIN3A*-specific TCCs, TCC88 responded well to the ps-SCL when these were presented by BLS cells transduced with HLA-DRA1*01 :01 and - DRB3*02:02 using IFN-y production as T cell activation readout. Most of the other TCCs did not respond to ps-SCL (data not shown).
[0129] We next created a scoring matrix using the median IFN-y values of three independent experiments and transforming these to log base 10 values. Following the in-silico predictions, over 300 peptides in the range between 60-100% of the maximum theoretical score (%) were synthesized and tested with TCC88 to assess and reconfirm the accuracy of the predictions. Of these, TCC88 recognized >80% of peptides within the score range of 90-100% of the maximum score.
[0130] For the identification of putative targets of TCC88, we searched several large databases including all human proteins, the translated transcriptome of the primary and recurrent autologous glioblastoma, all viruses, which are annotated for infecting humans, as well as UniProt-deposited bacteria and human gut microbiota (Almeida, A. et al. 2021 ibid) (see materials and methods section) (Fig. 3a). The number of unique 10-mer peptides within each of these databases is shown in Fig. 3a. Combined, these represent >5x109decamer peptides. We synthesized 542 peptides (see materials and methods section) with high predicted stimulatory scores (Fig. 3a) and tested them with TCC88. As previously shown for other TCC (Planas, R. et al. Science Translational Medicine 10, eaat4301 (2018); Jelcic, I. et al., Cell 175, 85-100. e23 (2018); Sospedra, M. etal., PLOS Pathogens 1 , e41 (2005); Zhao, Y. etal., The Journal of Immunology 167, 2130-2141 (2001); Wang, J. et al., Cell 183, 1264-1281 ,e20 (2020)), TCC88 recognized multiple peptides from different sources including the autologous tumor transcriptome, the human proteome, viruses, bacteria as well as gut microbiota (Fig. 3a). Interestingly, 57.7% of all stimulatory peptides were derived from bacteria and gut microbiota, 29.3% from tumor antigens containing TAAs derived from the autologous glioblastoma, while peptides derived from other human proteins and viruses represented only minor fractions (Fig. 3a). Following our above observation, we were particularly interested in the bacteria / microbiota-derived peptides that stimulated TCC88. We tested 126 bacteria- and 100 gut microbiota-derived peptides. Surprisingly, the TIL-derived, SIN3A*- specific TCC88 recognized 21 bacterial and 42 gut microbiota-derived peptides (Fig. 3a, b) and 34 of these equally well or even better at a single antigen concentration than the mutated tumor peptide while peptides from other sources did not show this effect (Fig. 3b, c). The recognition with high functional avidity by TCC88 was confirmed by dose titration of several bacteria / microbiota-derived peptides in the context of HLA-DRB3*02:02 (ECso~ 0.017, 0.018 and 0.019 pM for peptides HGM62 (Sedimentibacter), HGM3 ( ictivallis') and HGM27 (Prevotella) , respectively), which is similar to SIN3A* (ECso~ 0.018 pM) (Fig. 3d). Despite the remarkable cross-recognition of multiple tumor- and bacteria / microbiota-derived peptides, TCC88 did not respond to a large number of peptides (260 peptides) covering the whole protein sequence of several brain- and myelin, pancreas and skin autoantigens. TCC88’s response to unmutated SIN3A peptide confirmed that it weakly recognizes the wild type antigen. Upon activation by the cognate antigen or bacteria / microbiota-derived peptides, TCC88 shows a proinflammatory phenotype and secretes large quantities of IFN-y, GM-CSF, TNF-a and granzyme B (Fig. 3e). The release of CCL3 and CCL4 indicates that activated TCC88 may recruit other immune cells such as CD8+T cells (Fig. 3e). While the cytokine and chemokine responses of TCC88 to different antigens was overall comparable, there were some differences with higher amounts of IL-2 and fractalkine upon stimulation with SIN3A* and stronger secretion of IL-10 and CXCL10 with bacteria / microbiota-derived peptides (Fig. 3e). Further, comparable cytotoxic activity against autologous glioblastoma cells was induced by SIN3A* or HGM3 peptides (Fig. 3f). Noteworthy, due to slow in vitro growth of patient-derived tumor cells, only HGM3 peptide was tested since it has the same EC50 as the SIN3A* peptide for the clone. Hence, TCC88 strongly cross-recognizes tumor-antigens as well as bacteria / microbiota-derived peptides, which are mainly derived from Firmicutes, Proteobacteria or Bacteroidota phyla. In line with previous data and other clones (Planas, R. et al., 2018 ibid; Wang, J. et al., 2020 ibid), we were not able to discern common amino acid patterns in stimulatory peptides when compared with non-stimulatory ones. Among stimulatory peptides are peptides from several species including B. fragilis (HGM32 peptide), the importance of which had previously been shown in the context of immune checkpoint inhibitor therapies (Vetizou, M. et al., Science 350, 1079-1084 (2015)). Finally, stimulating TCC88 with both HGM3 and SIN3A* peptides did not have synergistic effects (Fig. 3g). Example 4: TILs recognize bacteria / microbiota-derived peptides
[0131] The above observation raised the question whether the reactivity of TCC88 against tumor antigens is unique for this clone or bacteria / microbiota-derived peptides could also be recognized by bulk TILs. We therefore tested the proliferative and cytokine responses of bulk TILs against the bacteria / microbiota- derived peptides that had been identified as targets for TCC88. Indeed, bulk TILs also recognized 23 bacteria / microbiota-derived peptides (Fig. 4a). To exclude that the response of bulk TILs is due to the fact that they contain TCC88, we tested additional TIL-derived TCCs that had been established by stimulation with SIN3A* peptide against the bacteria / microbiota-derived peptides. TCC68 and TCC75 also recognized both SIN3A* peptide and various bacteria / microbiota-derived peptides (Fig. 4b). However, not all SIN3A* peptide-responsive TCCs showed this reactivity pattern. As an example, TCC8F7, which strongly responds to the SIN3A* peptide and several other glioblastoma-derived peptides, does not recognize any of the bacterial antigens (Fig. 4b). Figure 4C summarizes the response of the TILs and the TCCs to bacteria / microbiota-derived peptides. Their reactivity against the peptides that had been selected based on the unbiased antigen search for TCC88 differed, but both TCC68 and TCC75 recognized several bacteria / microbiota-derived ones with different strengths (Fig. 4c). The comparison of the reactivity patterns between TCC88 and the bulk TILs as well as the two other TCCs shows that TILs contain multiple TCCs with different reactivity patterns, but clear responses to the bacteria / microbiota-derived peptides. To corroborate this point further, we compared the T cell receptor (TCR) expression of the TCCs. TCC88 expresses TCRBV6.1 , TCC68 and TCC75 express TCRBV6.2. We further stained TILs using a panel of 22 fluorescently labeled TCRBV antibodies that can detect 27 different TCRBVs excluding TCRBV6.1 and TCRBV6.2. Stained CD4+TILs were then sorted and rested for a day before testing them with peptides. The antibody panel stained approximately half of the TCRVps in the TILs and not only excluded TCRBV6.1 and -TCRBV6.2 but also those, for which no antibody is available. These depleted TILs still responded to bacterial peptides supporting the above point that bulk TILs contain several T cells that recognize bacteria / microbiota-derived peptides. Moreover, examining the cytokine / chemokine profile of TCC75 shows that it also secretes proinflammatory cytokines upon activation by either tumor neoantigen or Prevotella spp. (HGM27 peptide). It is noteworthy that TCC75 secretes higher IL-10 upon stimulation with tumor antigen showing that different TCCs may secrete different cytokines / chemokines upon stimulation with a similar antigen (Fig. 4d). Next, we compared the bacteria / microbiota-derived peptides that we identified for TIL-derived TCC88 with the IPdBPs of the tumor, but did not find shared sequences. However, some peptides derived from the same source bacterium including Bacillus sp. and Bacteroides ovatus indicating that TCC88 responded to peptides from different proteins of these bacteria. These results demonstrate that unbiased epitope discovery for a single TIL-derived TCC was informative regarding the reactivity of bulk T cells in that TILs were able to respond to various bacteria / microbiota-derived peptides.
[0132] Example 5: Cross-reactivity of TILs against tumor and bacterial antigens
[0133] Since several TIL-derived TCCs cross-recognize a tumor antigen and bacteria / microbiota-derived peptides, we addressed whether bulk TILs responding to bacteria / microbiota-derived peptides also recognize tumor antigens. CFSE-labeled TILs were stimulated with a pool of 22 peptides that had been applied in the vaccine of the patient and included somatic mutations and peptides derived from genes that were over-expressed in the autologous tumor (Fig. 4a) (Wang, J. et al., 2022 ibid). CFSE-labeled TILs were also separately stimulated with a pool of 23 bacteria / microbiota-derived peptides that were recognized by bulk TILs (Fig. 4a). Proliferative (CFSEdim) CD4+T cells were sorted at day 10. Part of the sorted cells were short-term expanded with PHA and IL-2 and the remainder used for TCR sequencing (Fig. 5a). A higher number of T cells within the bulk TILs responded to the vaccine peptide pool compared to bacteria / microbiota-derived peptide pool (Fig. 5a), but the CD4+TILs that had been stimulated with the bacteria / microbiota-derived peptide pool also recognized several tumor antigens including Laminin Subunit Alpha 5 (LAMA5), low-density lipoprotein receptor-related protein 6 (LRP6) and SIN3A* peptides as well as the pools of tumor antigens and bacteria / microbiota-derived peptides by proliferation and / or GM-CSF secretion (Fig. 5b). Moreover, short-term expanded CD4+TILs that responded to the bacteria / microbiota-derived peptide pool showed a comparable cytokine / chemokine profile including several proinflammatory cytokines (IFN-y, TNF-a, granzyme B) after activation with both peptide pools (Fig. 5c). When we compared TCR sequences of the CFSEdimCD4+T cells responding to the tumor vaccine pool with those responding to the bacteria / microbiota-derived peptide pool they share 3.7% of the TCRs indicating that these T cells are cross-reactive against tumor- and bacterial antigens (Fig. 5d). The fraction of TCRs that are found in both expanded T cell fractions makes up 1 % of the entire TILs (Fig. 5e). From the above TIL-derived TCCs we only identified TCC75 and TCC88 in the TCR data of both CFSEdimfractions indicating that the fractions of cells that were isolated for TCR sequencing were too small.
[0134] Example 6: Bacteria-reactive peripheral CD4+T cells respond to tumor antigens
[0135] When considering bacteria / microbiota-derived peptides for future vaccination approaches, it will be important to show that they induce a tumor-specific immune response in the peripheral immune system. To address if T cells with reactivity against bacterial peptides that had been identified by the TCC88 profiling also stimulate peripheral blood memory cells, we CFSE-labeled CD45RA- cells from PBMCs and activated these with the above pool of bacteria / microbiota-derived peptides that were stimulatory for TILs. CD4+T cells responded substantially stronger than CD8+T cells to this peptide pool (Fig. 6a). Proliferating CFSEdimCD4+T cells were then sorted and short-term expanded with PHA and IL-2 (Fig. 6a). CFSEmidCD8+T cells (Fig. 6a) were not followed further.
[0136] We next addressed if the sorted and short-term expanded peripheral memory CD4+T cells, which had been preselected by a pool of bacteria / microbiota-derived peptides, responded to the peptides derived from TSAs and TAAs of the autologous tumor. Interestingly, these cells recognized three tumor antigens via proliferation while unselected peripheral memory T cells did not (Fig. 6b). In addition to antigen-specific proliferation, they showed robust production of various cytokines / chemokines in response to the LRP6 peptide in the selected population compared to the unselected cells (Fig. 6c). We next asked whether these peripheral blood CD4+T cells can be found in the TILs by comparing the TCR sequences of bacteria / microbiota-reactive peripheral CD4+memory T cells with bulk TILs (Fig. 6d) and TILs selected by stimulation with bacteria / microbiota-derived peptide pool (Fig. 6e). 1.8% of the peripheral blood-derived bacteria / microbiota-responsive T cells are also present in bulk TILs (Fig. 6d). Further, 2.8% of the T cells are present in both the selected peripheral T cells and TILs responding to bacteria / microbiota-derived peptide pool (Fig. 6e). To return to our starting observation with IPdBPs, we examined if T cells with specificity for these also exist in peripheral blood memory T cells and whether they respond to autologous tumor antigens. We stimulated CFSE-labeled peripheral memory CD4+T cells with all 37 IPdBPs, sorted the proliferating cells and short-term expanded them. Surprisingly, these bacteria-activated memory T cells recognized the same three tumor antigens which are recognized by peripheral T cells that had been selected with bacteria / microbiota-derived peptides via proliferation and / or GM-CSF cytokine expression as indicators for T cell activation. Furthermore, the cytokine / chemokine profile of immunopeptidome- reactive peripheral CD4+T cells stimulated with the tumor peptide (LRP6) as well as the pool of IPdBPs showed that T cells secreted not only GM-CSF, but also several other pro-inflammatory cytokines including IFN-y, TNF-a and granzyme B. To address, if there was an overlap between peripheral blood memory T cells responding to IPdBPs and the bulk TILs we sequenced the TCRVp repertoires of both populations and found that indeed 0.5% of the TCR sequences were shared. This indicates that T cells responding to bacterial antigens, which are presented in the tumor, can be found in the peripheral immune compartment as well. As another means to show that peripheral blood CD4+T cells that had been activated with bacteria / microbiota- or IPdBPs recognized the same tumor antigens, we compared the TCR sequences of these two populations. These data support the cross-reactivity results. 3.4% of the TCR sequences were shared between the two populations, and most of these TCRs were clonally expanded in each group. Finally, to assess whether the bacteria / microbiota-derived peptides that were recognized by TCC88 and TILs from patient 1635WI were only stimulatory for T cells of this patient or also for TILs from another glioblastoma patient, we tested TILs reactivity from another glioblastoma patient (GBM-40). Indeed, TILs (GBM-40) recognized several bacteria / microbiota-derived peptides from patient 1635WI, albeit less strongly.
[0137] These data show a) that T cells with reactivity against bacterial peptides that are presented on HLA-DR molecules, i.e. the immunopeptidome, within the tumor exist in the peripheral blood, b) that memory T cells that recognize bacteria / microbiota that had been identified by analyzing a tumor neoantigen- reactive TCC can be found in the periphery and TILs, and c) that a fraction of T cells from both a) and b) respond also to tumor antigens.
[0138] Example 7 Discussion
[0139] Our study examines the role of bacteria for tumor antigen-specific immune responses in a tumor with poor prognosis and high unmet medical need for improving therapeutic options, i.e. glioblastoma. We build on recent highly interesting observations about the possible roles of bacteria and in particular the "resident" gut microbiota regarding a host of influences on shaping the immune system. Particularly the findings that bacterial communities can be found in tumors including glioblastoma, the demonstration of bacterial peptides in the immunopeptidome of tumors and the influence of commensal bacteria and a bacteriophage on stimulating tumor-specific immune responses led us to examine potential roles of tumor-associated microbiota in detail. In a first step, we confirmed data by Nejman et al. (Nejman, D. et al., 2020 ibid) that bacteria-derived sequences are found in glioblastoma and by Kalaora et al. (Kalaora, S. et al., 2021 ibid) regarding the presence of bacteria / microbiota-derived peptides in the HLA-DR immunopeptidomes of patients, however not in melanoma, but glioblastoma. The number of peptides and bacterial strains, from which the IPdBPs were derived, varied between 5 to more than 50 different peptides. Hence, compared to the number of tumor- or generally human protein-derived peptide sequences, which usually are a few thousands (Fig. 1 cl), the relative abundance of bacterial peptides in the HLA-ll-immunopeptidomes was low. This may be due to several reasons including the low burden of bacteria in the tumor cells and / or on tumor-infiltrating APCs with the consequence that bacterial peptides occupy only a minority of HLA-II molecules and may therefore fall below the limit of detection of the employed LC-MS / MS system. Consistent with Nejman et al., we found Proteobacteria and Firmicutes phyla as most prevalent in glioblastoma . (Nejman, D. et al., 2020 ibid). Although we focused on immunopeptidome-derived bacterial sequences, both analyses demonstrate the presence of bacterial antigens of Enterobacterales, Burkholderiales, Bacillales, Clostridiales and others at the orderlevel phylotypes. In a patient, whom we had previously treated with a personalized vaccination using cocktails of peptides from tumor neoepitopes as well as from proteins that were overexpressed in the tumor, we tested if IPdBPs are recognized by TILs. Compared to the mutated SIN3A* peptide, which had been included in the vaccine, TILs responded very weakly to 3 out of 37 IPdBPs via proliferation, however, the secretion of GM-CSF and TNF-a as well as the proinflammatory chemokine CXCL10 that enhances the trafficking of cytotoxic CD8+T cells to tumors support the reactivity. Interestingly, CXCL10 has been used to predict the responses to anti-PD1 treatment in several tumors including melanoma and gastric cancer. Next, when examining proinflammatory SIN3A*-reactive TCCs, 2 out of 10 recognized single (TCC-57) or multiple (TCC-2D3) IPdBPs demonstrating that T cells with crossreactivity against tumor and IPdBPs can be found in the TILs. With an unbiased antigen discovery approach, we had previously successfully identified targets for autoreactive-, virus- and bacteria-specific CD4+TCCs that these can recognize multiple antigens (Planas, R. et al. 2018 ibid; Jelcic, I. et al., 2018 ibid; Sospedra, M. et al., 2005 ibid; Zhao, Y. et al., 2001 ibid; Wang, J. et al., 2020 ibid). Therefore, here we addressed, now starting from tumor-infiltrating T cells, whether TIL-derived TCCs would respond to viral-, bacterial-, microbiome-, human protein- or tumor antigen-derived peptides. TIL-derived, SIN3A*- specific TCC88 served as prototypic example to search for predicted target antigens among sequences of all human proteins, viruses and bacteria with tropism for humans, gut microbiota, the translated proteome of the autologous primary and recurrent tumor and the tumor immunopeptidome. The sizes of these databases ranged between 16000 (immunopeptidome) to more than 3.4 billion (human gut microbiota) peptides (Fig. 3a). We mainly considered peptides with predicted stimulatory scores between 80-100% (see materials and methods) of the maximal score of TCC88 and synthesized 542 peptides from these different sources (Fig. 3a). The TCC responded to 109 of these peptides, and, among these, reactivity was broadest to bacterial and microbiota-derived peptides, but also to many tumor proteome-derived peptides (Fig. 3a). Of 226 bacterial / microbiota peptides TCC88 recognized 63 individual peptides, and 34 stimulated TILs strongly. Besides two species including B.Ovatus and Bacillus sp., other bacteria / microbiota-derived peptides that we found with the unbiased antigen search were derived from completely different bacterial species than those derived from the immunopeptidome. These data show that tumor-infiltrating TCCs may cross-recognize not only single bacterial, viral or phage-derived peptides, but also large number of peptides from both pathogenic bacteria and gut microbiota-derived commensals. Similar to previous data with autoreactive TCCs in multiple sclerosis, we did not identify amino acid patterns or HLA- / TCR binding motifs that allow to distinguish stimulatory from non-stimulatory peptides, and thus might explain the broad cross-reactivity. The primary HLA restriction element is DRB3*02:02, but similar to virus-specific and autoreactive TCCs that we had described previously (Yousef, S. et al., The Journal of Immunology 189, 3618-3630 (2012); Wang, J. et al., 2020 ibid), TCC88 is cross-restricted, i.e. capable of recognizing peptides also in the context of other autologous HLA-DR molecules. The absence of easily discernible similarities between the peptides that TCC88 recognizes is likely explained by the unbiased search algorithm, which assumes that each amino acid of a peptide contributes individually and additively to HLA- and / or TCR binding and that it is the sum of these contributions rather than their sequence or motifs that determines the stimulatory potency. With respect to the functional response of TCC88 to tumor antigen-derived and bacterial peptides, we show both in vitro cytotoxicity against an autologous glioblastoma cell line and a multifunctional proinflammatory phenotype with strong secretion of TNF-a, IFN-y, granzyme B, GM-CSF and others. While the response to SIN3A* and two bacterial peptides is almost identical the relatively higher secretion of IL-10 upon stimulation with the bacterial peptides may indicate that the latter may both activate, but also dampen intratumoral T cell responses.
[0140] These data raised several important questions including whether TCC88 is an unusually cross-reactive clone among the TILs and whether the bacteria / microbiota-derived peptides that were recognized by TCC88 could also stimulate the bulk TIL population. Indeed, both were the case. 23 of the 63 bacteria / microbiota-derived peptides that were recognized by TCC88 also stimulated bulk TILs, and several of these also other SIN3A*-specific, TIL-derived TCCs underscoring that reactivity of CD4+TCC against bacterial and microbial peptides within glioblastoma is broad. Further, the diversity of the TIL response against bacterial and microbiota is supported by the fact that there are SIN3A*-specific TCCs (TCC68 and -75) that responded to bacteria / microbiota-derived peptides that had been identified by the unbiased search for targets with TCC88, while other clones such as TCC 8F7 did not recognize the latter.
[0141] The above observations demonstrate that glioblastoma-infiltrating TILs can recognize multiple peptides from bacteria and gut microbiota, and the immunopeptidome analyses reveal that such peptides might be locally presented in the tumor. Tumor-specific and bacteria / microbiota cross-recognizing TCCs are proinflammatory and can kill autologous tumor cells. If one wanted to employ this knowledge for tumor vaccination in the future, it is of interest to examine the response against tumor- and bacteria / microbiota- derived peptides also in peripheral blood memory T cells. Following stimulation of peripheral blood memory T cells with bacteria / microbiota-derived peptides derived either from the target search for TCC88 or from the tumor immunopeptidome indeed not only identified reactivity against bacterial targets from both sources, but also reactivity against tumor antigens. Moreover, at the level of bulk peripheral blood memory T cells that had been pre-stimulated with either bacteria / microbiota-derived peptides or with several tumor-derived antigens, cross-reactivity, which was shown at the clonal level for TCC88, likely exists for more T cells within these T cell populations based on comparing their TCR repertoire. Particularly noteworthy, one of the tumor antigens, a peptide from LRP6, was recognized by buIk T cells after pre-stimulation with both bacteria / microbiota and immunopeptidome-derived bacterial peptide pools. LRP6 is a co-receptor in the Wnt signaling pathway that supports the proliferation of tumor cells, and several lines of evidence have shown that inhibition of LRP6 leads to suppression of tumor cell proliferation and enhances chemosensitivity of cancer cells52. These data indicate that peripheral blood memory T cells show overlap with the reactivity of TILs, which is supported by TCRVp sharing between these different populations.
[0142] Our data highlight several important points. The immunopeptidome analyses suggest that bacteria and gut microbiota can exist within glioblastoma and that peptides from these are presented by HLA- molecules on tumor cells, and likely also on local APCs. Thus, we confirm prior data from melanoma and extend these by showing that some immunopeptidome-derived peptides are weakly recognized by both individual tumor-specific TCCs and bulk CD4+TILs. Further, systematic unbiased epitope mapping of tumor-specific TCCs identified novel bacteria / microbiota-derived antigens, which were highly stimulatory for clones and bulk TILs. Noteworthy, we confirm that individual TCCs can not only recognize single bacterial or phage-derived peptides, but be broadly cross-reactive with multiple bacteria / microbiota-derived peptides that are identifiable by unbiased target searches. Such crossreactivity patterns may explain the response of cancer patients with certain gut microbiota composition to immune checkpoint inhibitors. Vetizou and colleagues found that Bacteroides fragilis induced a Th1 phenotype which led to restoration of treatment responsiveness to CTLA-4 blockade in tumor-bearing germ free mice. Mice transplanted with feces of CTLA-4 responsive melanoma patients with high Bacteroides fragilis abundance also responded to the blockade (Vetizou, M. et al, 2015 ibid). Moreover, Ruminococcus bromii is prevalent in the gut of melanoma patients that respond to anti-PD1 therapy, and Faecalibacterium of the Ruminococcaceae family was proposed to favor such responses. Other bacteria such as Alistipes spp., and Eubacterium spp. were found to be enriched in the gut microbiota of non-small cell lung carcinoma (NSCLC) patients responding to anti-PD1 therapy. Alistipes indistinctus can restore the response to checkpoint blockade in mice. Interestingly, using our unbiased approach we found peptides from Bacteroides fragilis, Ruminococcus bromii, Alistipes and Eubacterium genus that were stimulatory for TCC88. This observation provides further hints at T cell cross-reactivity as a possible mechanism of effective immunotherapies due to certain gut microbiota composition. Our data indicate that not only commensals but peptides from certain pathogenic bacteria may be exploited for strong stimulation of T cells against cancer cells. The reactivity of peripheral blood memory T cells against both bacteria / microbiota-derived- as well as tumor peptides may be used for vaccination approaches that combine tumor-derived- and bacteria / microbial peptides, use mRNAs encoding such combinations of tumor / self- and foreign antigens or even adoptive T cell therapies with TCCs like TCC88 or TCC-2D3 or their TCRs. The recent observation that bacteria can be involved in tumor metastasis suggests, therefore, that T cell activation against bacteria and tumor cells may not only be used early in the disease but even at later stages after cancer metastasis.
[0143] Limitations of our study include that we could not examine the "autologous" gut microbiota of patients, their lung microbiome, which appears to play an important role in brain homing of proinflammatory T cells, and also that the most detailed studies on both tumor immunopeptidome and its annotation to bacteria / microbiota, unbiased target discovery for TIL-derived TCC and their cross-reactivity against bacteria and tumor antigens mainly derive from one patient. However, we identified TIL reactivity against some of the bacteria / microbiota-derived peptide targets from patient 1635WI already in TILs from another glioblastoma patient. Furthermore, the three different methodologies, i.e. 16S rRNA sequencing, immunopeptidomics and unbiased target discovery for a TIL-derived T cell clone, identify largely non-overlapping bacterial and gut microbiata-derived species and peptides. All suggest an involvement of bacteria and gut microbiota in the tumor's biology and / or immune defense against it, however, future studies will need to examine their roles in more depth.
[0144] In order to explore the above therapeutic applications further, strong emphasis would have to be laid on rapid analysis of the tumor immunopeptidome for bacteria / microbial sequences and / or even better the unbiased target discovery for TIL-derived clones, and de-risking potential reactivity against vital organs should be incorporated. Our findings support that this is in principle possible and that intratumoral bacteria and gut microbiome communities likely play a role in tumor defense mechanisms and could be exploited systematically in the context of immune checkpoint inhibitor- and personalized cancer therapies.
[0145] Example 8: Material and Methods
[0146] Patient information and materials
[0147] Patient 1635WI, who was treated with a personalized neopeptide vaccination, was a 55 year-old male diagnosed with glioblastoma. After resection, he was treated with standard radiochemotherapy and additionally the immune checkpoint inhibitor pembrolizumab (anti-PD-1), and the anti-VEGF monoclonal antibody bevacizumab. He was interested in participating in an individual treatment attempt with a personalized peptide vaccination therapy (Wang, J. et al., 2022 ibid). He was fully informed about the potential risks of such a vaccination, which, by definition, is an individual medical treatment (“compassionate use") and not subject to special regulations for medical research according to the Therapeutic Products Act (TPA) or Swiss Federal Human Research Act (HRA). Consequently, individual medical treatments are not approved by the Ethics Committee or Swiss Agency for Therapeutic Products (Swissmedic), as they do not constitute clinical trials for the purpose of systematically gaining knowledge. The patient gave written informed consent to receive the individualized vaccination.
[0148] The cohort of 18 additional glioblastoma patients includes the primary tumor of 16 patients and 2 recurrent tumors from 2 patients, all from the University Hospital Zurich, Zurich, Switzerland. Tumor tissues were immediately frozen after surgery and stored at -80°C until immunoaffinity purification of HLA-peptide complexes. Autologous tumor cells were also isolated and frozen from several samples (n=6) and immunopeptidomes analyzed. Written informed consent was obtained from each patient in accordance with the local ethical requirements (KEK-ZH-Nr. 2015-0163). To generate autologous tumor cell lines, tumor tissue was washed thoroughly using PBS. Next, they were cut into small pieces and treated with digestion mix including RPMI-1640 medium (Sigma-Aldrich, Missouri, USA) containing 10% FCS (Eurobio, Courtaboeuf, France), 1 mg / ml of collagenase IV (Sigma-Aldrich), 0.1 mg / ml of DNasel (Sigma-Aldrich) and incubated for 42 minutes at 37 °C. The reaction was stopped by adding PBS with 2mM EDTA (Invitrogen, MA, USA) and the lysate were passed through a filter mesh. Next, tumor cells were isolated using Percoll (Sigma-Aldrich) gradient. Isolated cancer cell lines were passaged up to 30 times to make sure no other cells are present before they were snap froze and used for the immunopeptidome analyses. DNA extraction and genotyping
[0149] DNA was extracted from PBMCs, tumor cells and tissues of glioblastoma patients using DNeasy Blood & Tissue Kits (Qiagen, Hilden, Germany). The genotyping of HLA-class I and HLA-class II was done by high-resolution HLA sequence-based typing (Histogenetics, NY, USA).
[0150] PBMCs, cell lines, and T cell clones
[0151] PBMCs of patient 1635WI were isolated from a leukapheresis, and allogenic PBMCs were isolated from buffy coats by Ficoll (Eurobio, Courtaboeuf, France) density gradient centrifugation.
[0152] BLS-DRB1 *03:01 (kindly gifted from William W. Kwok, Benaroya institute, WA, USA), BLS-DRB1 *04:02, BLS-DRB3*02:02 and BLS-DRB4*01 :01 are EBV-infected B cells from a bare lymphocyte syndrome type II patient that are transfected with single HLA-DR molecules of the glioblastoma patient. Thus, each BLS DR transfectant expresses a single HLA-DR molecule. Briefly, various HLA-DRB cDNAs were inserted after CMV promoter in a pLenti-CMV vector (kindly provided by Michael Scharl, University of Zurich). Plasmid vectors carrying different HLA-DRBs were used to prepare lentiviruses using pCMV- dR8.91 (packaging plasmid) and pMD2.G (VSV-G envelope plasmid) (both kindly gifted by Michael Scharl, University Hospital Zurich). Next, BLS cells expressing HLA-DRA1*01 :01 (kindly provided by William W. Kwok, Benaroya institute, WA, USA) were transduced with various HLA-DRB lentiviruses and cells selected using blasticidine after 7 days. BLS cells are maintained and expanded using RPMI- 1640 medium (Sigma-Aldrich, Ml, USA) containing 10% heat-inactivated fetal calf serum (FCS; Eurobio, Courtaboeuf, France), 2mM L-glutamine (Thermo Fisher Scientific, MA, USA), 100 U / ml penicillin (Corning, NY, USA) and 100 pg / ml streptomycin (Corning, NY, USA). Bulk TILs and isolated TCCs including TCC88 and other TCCs were expanded using irradiated allogenic PBMCs (45 Gy) in T cell medium containing IMDM (GE Healthcare, IL, USA), 5% heat-inactivated human serum (Blood Bank Basel, Switzerland), 1 pg / mL phytohemagglutinin (PHA), 20 U / ml of human IL-2 (h-IL-2), 2 mM L- glutamine (Thermo Fisher Scientific, MA, USA), 100 U / ml penicillin (Corning, NY, USA) and 100 pg / ml streptomycin (Corning, NY, USA). The medium was changed every 3-4 days and new h-IL-2 added each time.
[0153] Proliferation assay
[0154] All peptides were synthesized with acetylated N-terminus and amidated C-terminus (Peptides&Elephants, Hennigsdorf, Germany). Proliferation of TCCs and bulk TILs was measured using3H-thymidine incorporation (Hartmann Analytic, Braunschweig, Germany) assay after 3 and 5 days, respectively. Isolated TCCs (2 x 104cells / well) were co-cultured with irradiated BLS cells (300 Gy) (5 x 104cells / well) in 200 pl of X-VIVO 15™ medium (Lonza, Switzerland) and seeded in 96-well U-bottom plates (Greiner Bio-One, Austria). Bulk TILs (5 x 104cells / well) were co-cultured with irradiated autologous PBMCs (45 Gy) (2 x 105cells / well) in 200 pl of X-VIVO 15™ medium (Lonza, Switzerland) and seeded in 96-well U-bottom plates (Greiner Bio-One, Austria). Peptides were then used at a final concentration of 10 pM to stimulate the TCCs or bulk TILs. Results are shown as stimulatory index (SI), i.e. the ratio of count per minute (CPM) in the presence of the peptides divided by the negative control (no peptide). SI > 2 is considered positive. For testing peripheral blood memory T cells, CD45RA- cells were isolated using human CD45RA microbeads (Miltenyi, Bergisch Gladbach, Germany). Negatively selected CD45RA- cells were seeded (2 x 105cells / well) in 200 pl of X-VIVO 15™ medium (Lonza, Switzerland) in 96-well U-bottom plates (Greiner Bio-One, Austria). Peptides were then added at a final concentration of 10 pM and incubated for 7 days before measuring their proliferation via3H-Thymidine incorporation.
[0155] To isolate antigen-reactive T cells from the TILs or peripheral T cells, carboxyfluorescein succinimidyl ester (CFSE, Sigma-Aldrich, Ml, USA) was used to label the cells. Briefly, cells were incubated with CFSE (final concentration of 0.5 pM) for 3 minutes at room temperature. Next, the labeling was immediately stopped using a serum-containing medium and washed before cells were seeded at (5 x 104cells / well) in the presence of irradiated autologous PBMCs (45 Gy) (2 x 105cells / well) in 200 pl of X-VIVO 15™ medium (Lonza, Switzerland) and the peptide of interest. After 10 days, cells were pooled, washed once with X-VIVO 15™ medium (Lonza, Switzerland) and stained with live-dead yellow (Invitrogen, MA, USA) as well as surface markers and cells sorted with a SH800S Cell Sorter (Sony).
[0156] Sorting bulk T cells
[0157] TILs expressing specific TCRBVs were isolated from bulk TILs using a panel of 22 fluorescently labeled TCRBV antibodies that detect 27 different TCRBVs. 12 TCRBV antibodies are labeled with PE and 10 with FITC (Beckman coulter, CA, USA). 5 million TILs that had been expanded once with the above protocol were thawed and washed once with PBS before incubation with human lgG(1 :25) (Sigma- Aldrich, Ml, USA) for 30 minutes to block Fc fragments and reduce non-specific antibody staining. After another wash, cells were stained with CD4(1 :100) (APC anti-human CD4, eBioscience), CD8(1 :100) (Pacific blue anti-human CD8, Biolegend, CA, USA), TCRBV-PE(1 :25) (Beckman coulter, CA, USA) and TCRBV-FITC(1 :25) (Beckman coulter, CA, USA) antibodies for 30 minutes. Finally, cells were sorted, seeded at 5 x 104cells / well in T cell medium without h-IL-2 and rested for one day before stimulation with 2 x 105cells / well irradiated autologous PBMCs (45 Gy) and peptide (10 pM).
[0158] Further, TILs were CFSE-labeled and 5 x 104cells / well stimulated with irradiated autologous PBMCs (2 x 105cells / well) and pools of 22 glioblastoma-associated peptides that had been used in an individualized vaccination of patient 1635WI (Wang, J. et al., ibid) or 23 bacteria / microbiota-derived peptides, which had been identified by an unbiased target search for TCC88 (see below). Both peptide pools have a final concentration of ~25 pM for all the peptides in the pool, and the DMSO concentration was always lower than 0.5%.
[0159] Regarding isolation of peripheral memory T cells, CD45RA- cells were sorted using human CD45RA microbeads (Miltenyi, Bergisch Gladbach, Germany) and CFSE-labeled. Next, 2 x 105cells / well were seeded in 200 pl of X-VIVO 15™ medium (Lonza, Switzerland) in 96-well U-bottom plates (Greiner Bio- One, Austria) in the presence of the bacteria / microbiota-derived peptide pool or the IPdBP pool. The IPdBP pool contains 37 H LA- 11 -de rived bacterial peptides at the final concentration of 20 pM for all the peptides in the pool. After 10 days, cells were Fc-blocked using human lgG(1 :25) (Sigma-Aldrich, Ml, USA) and labeled with live-dead yellow(1 :1000) (Invitrogen, MA, USA), PerCP-Cy5.5 anti-human CD3(1 :100) (Biolegend, CA, USA), APC anti-human CD45RA(1 :50) (Biolegend, CA, USA), APC-Cy7 anti-human CD4(1 :100) (Biolegend, CA, USA) and Pacific blue anti-human CD8(1 :100) (Biolegend, CA, USA). CD45RA- CD3+CD4+CFSEdim cells were then sorted and 2 x 104cells / well seeded in 96-well U- bottom plates (Greiner Bio-One, Austria) with irradiated allogenic PBMCs, PHA and h-IL-2 as described above. Medium was changed every 3-4 days and new h-IL-2 was added each time. If necessary, each well was split into two. After 14 days cells were cryopreserved.
[0160] T cell cloning and characterization
[0161] To generate CD4+T cell clones, bulk TILs were CFSE-labeled and stimulated with SIN3A* peptide (10 pM). After 10 days, live proliferative (CFSEdim), CD3+(1 :100) (PerCP / Cy5.5 anti-human CD3 antibody, Biolegend, CA, USA), CD4+(1 :100) (APC-Cy7 anti-human CD4 antibody, Biolegend, CA, USA) T cells were single-cell sorted into 96-well U-bottom plates (Greiner Bio-One, Austria). Cells were then expanded using irradiated allogenic PBMCs in the presence of PHA and h-IL-2 in T cell medium. The medium was changed every 3-4 days and h-IL-2 added each time until day 12. Cells were then subjected to rapid expansion to expand TCCs. 5 x 104TCCs were transferred into T25 flasks (TPP) and were expanded using 3 x 107irradiated allogenic PBMCs (45 Gy) in T cell medium containing anti-CD3 monoclonal antibody (OKT3) (Ortho Biotech). After 1 day, h-IL-2 was added at 50 U / ml and at day 5 the content of the flask was harvested, spun down and resuspended in new T cell medium containing 50 U / ml of h-IL-2. At day 8, cells were split into new T25 flasks and 20 U / ml of h-IL-2 was added. At day 16 cells were harvested, washed and cryopreserved in freezing medium including 90% heat-inactivated FCS and 10% dimethyl sulfoxide (DMSO) (Applichem, Darmstadt, Germany).
[0162] TCCs were characterized using primers forTCRVp chains and further sequencing of amplicons (Yousef, S. et al., 2012 ibid). In addition, LEGENDplex Multi-Analyte Flow Assay kit (Biolegend, CA, USA) was used to identify the functional phenotype of TCC by measuring multiple cytokines in the supernatant following activation with anti-CD2 / CD3 / CD28 antibody-loaded MACSibead (Miltenyi, Bergisch Gladbach, Germany). The HLA-DR restriction of TCCs was defined by co-culturing TCCs with the four aforementioned irradiated HLA-DR transfected BLS cells (300 Gy) presenting different concentrations of the cognate antigen and measuring proliferation after 3 days using3H-thymidine incorporation.
[0163] Cytokine measurements
[0164] Supernatants from each experiment were harvested a day before adding thymidine and frozen at -20 °C. Cytokines were measured using ELISA for human IFN-y ELISA MAX™ (Biolegend, CA, USA), human GM-CSF DuoSet ELISA (R&D systems, Ml, USA) and bead-based assays. Synergy H1 hybrid multi-mode reader (Agilent, CA, USA) was used to measure the absorbance. LEGENDplex Multi-analyte Flow Assay kit (Biolegend, CA, USA) is a 13-plex human Th cytokine panel which includes IFN-y, TNF- a, IL-2, -4, -5, -6, -9, -10, -13, -17A, -17F, -21 , and -22. Staining was conducted as suggested by the manufacturer. LSR Fortessa Flow Cytometer (BD Biosciences, NJ, USA) was used to measure cytokines, and data were analyzed using FlowJo (Tree Star). Human XL Cytokine Luminex Performance Assay Fixed Panel (R&D Systems, Ml, USA) contains 45 analytes covering a broad range of various chemokines and cytokines. Bio-Plex 200 systems (BIO-RAD, CA, USA) was used to measure cytokine and chemokine secretion as suggested by the manufacturer. Positional scanning combinatorial peptide libraries (ps-SCL) and biometrical analysis
[0165] A library of L-amino acid decapeptide ps-SCL mixtures was prepared as mentioned before (Pinilla, C., et al., Biochemical Journal 301 , 847-853 (1994)). TCC88 is a CD4+T cell clone isolated from the TILs and is restricted by HLA-DRB3*02:02. Irradiated BLS-DRB3*02:02 cells (300 Gy) were incubated with 200 mixtures from the library at 200 and 100 pg / ml concentration. TCC88 was then co-cultured with these cells. Each well contained 2 x 104TCC88 and 5 x 104BLS cells. After 72 hours, supernatants were harvested and tested for IFN-y secretion by ELISA (Biolegend, CA, USA). Next, a scoring matrix was generated via log base 10 transformation of median IFN-y values of three independent experiments. Next, the biometrical analysis (Zhao, Y. et al., 2001 ibid) was used to score all 10-mers from several large databases, i.e. all human proteins (Swiss-Prot-20201202), the translated transcriptomes of the primary and recurrent autologous glioblastoma tumor (patient 1635WI), all viruses, which are annotated for infecting humans in UniProt (Swiss-Prot-20210305), as well as all bacteria (Swiss-Prot-20201202) and human gut microbiota (Almeida, A. etal., 2021 ibid). To assess the validity of the in silico predictions of stimulatory peptides for TCC88, consecutive 10-mer peptides with highest predicted scores in each database were synthesized and tested for their capacity to stimulate TCC88. Peptides were selected based on their predicted stimulatory scores and not other factors such as their source. Peptide scores ranged between 80-100% of the maximum theoretical score for all databases beside the tumor immunopeptidome (annotated by human proteins), which contained only few peptides with score over 80%. Therefore, we also synthesized several peptides within an extended score range between 60- 80%. Peptides were tested at a final concentration of 10 pM on irradiated BLS-DRB3*02:02 and cocultured with TCC88 as mentioned before.3H-Thymidine incorporation (Hartmann Analytic, Braunschweig, Germany) was used to measure proliferation.
[0166] T cell cytotoxicity assay
[0167] Briefly, TCC88 (2 x 104cells / well) was stimulated using tumor antigen SIN3A* and Victivallis gut bacterium HGM3 peptides (2 pM) separately on irradiated autologous PBMCs (1 x 105cells / well) for 72 hours in X-VIVO 15™ medium (Lonza, Switzerland). Next, the cells were pooled and washed once with X-VIVO 15™ medium (Lonza, Switzerland). Autologous glioblastoma cells were stained with PKH26 Red Fluorescent Cell Linker Kit (Sigma-Aldrich, Ml, USA) for 3 minutes and immediately washed 3 times with serum-containing medium. Target cells were then resuspended in X-VIVO 15™ medium (Lonza, Switzerland) and seeded at 2 x 104cells / well. Activated and rested TCC88 cells were co-cultured at 1 :1 and 5:1 effector to target (E:T) ratios in duplicates. Next, the plate was centrifuged at 80 g for 1 minute to ensure cell-cell contact. After 24 hours, supernatants were removed and cells detached using accutase (Thermo Fisher Scientific, MA, USA), washed and stained with LIVE / DEAD™ Fixable Near- IR Dead Cell Stain Kit (Thermo Scientific, MA, USA) and the percentage of PKH26+Near-IR+dead tumor cells was assessed using a BD LSR Fortessa. HLA-DR expression of cancer cells was also measured using PE-Cy7 anti-human HLA-DR antibody(1 :50) (Biolegend, CA, USA). In order to calculate the specific T cell-mediated cytotoxicity, target cells were separately seeded without TCC88 and their death (%) was considered as unspecific background death. TCRV / 3 sequencing
[0168] To compare TCRVp sequence of TILs responding to vaccine peptide pool with those responding to the bacteria / microbiota-derived peptide pool, CFSE-labeled TILs were seeded at 5 x 104cells / well in a 96- well U-bottom plates (Greiner Bio-One, Austria) and stimulated with the corresponding peptide pools incubated with irradiated autologous PBMCs (2 x 105cells / well). After 10 days, between 5-10 x 103live CD3+CD4+CFSEdim cells were sorted from each sample. Moreover, to isolate peripheral T cells responding to bacteria / microbiota-derived peptides or IPdBP pool, CFSE-labeled cells were sorted. Sorted cells from both experiments were spun down and supernatants removed. The pellet was snap- frozen immediately. DNeasy Blood & Tissue Kits (Qiagen, Hilden, Germany) was used to extract the DNA and amplification and sequencing of TCRVp CDR3 was performed using the ImmunoSEQ platform (Adaptive Biotechnologies, Seattle, WA, USA). For the TCR data analysis, non-productive TCRVp sequences were excluded and shared unique productive TCRVp sequences were specified based on identical CDR3 sequence as well as V and J chains. Representation of data was done using VENNY2 1(BioinfoGP, CNB-CSIC) (Oliveros, J. et al., https: / / bioinfogp.cnb.csic.es / tools / venny / (2007)).
[0169] IFN-y fluorospot assay
[0170] 2x104TILs / well were seeded with 5x104irradiated (300 Gy) autologous EBV-transformed B cell line cells (BLCLs) / well as APCs primed with bacteria / microbiota-derived peptides (10 pM final concentration). Cells were seeded in X-VIVO 15™ medium (Lonza, Switzerland) in human IFN-y / IL- 10 / IL-17A pre-coated fluorospot plates (FSP-010703-10, Mabtech, Sweden) and were incubated for 44 hours at 37 °C. Prior to seeding, fluorospot plates were washed 3 times using PBS and then blocked with RPMI-1640 medium (Sigma-Aldrich, Ml, USA) containing 10% FCS (Eurobio, Courtaboeuf, France) as instructed by the manufacturer. After 44 hours incubation, plates were washed using PBS and incubated with detection antibody, anti-IFN-y mAb 7-B6-1-BAM for 2 hours. Next, plates were washed using PBS and incubated with anti-BAM-490 fluorophore conjugate for 1 hours. Both detection antibody and fluorophore conjugate were diluted with PBS containing 0.1 % BSA (Sigma-Aldrich, Ml, USA) as instructed by the manufacturer. Next, plates were washed using PBS and incubated with fluorescence enhancer (Mabtech, Sweden) for 15 minutes. Plates were emptied by flicking and kept in dark for 24 hours to completely dry. Finally, spot analysis is performed using automated Mabtech IRIS fluorospot reader (Mabtech, Sweden).
[0171] Immunopeptidome analyses
[0172] In order to analyze the immunopeptidomes of the tumor tissues and cell lines, frozen tissues and frozen cell pellets were homogenized in CHAPS-containing lysis buffer to perform standard immunoaffinity chromatography. Briefly, tumor tissues were washed thoroughly using PBS. Next, they were cut into small pieces and treated with digestion mix including RPMI-1640 medium (Sigma-Aldrich, Ml, USA) containing 10% FCS (Eurobio, Courtaboeuf, France), 1 mg / ml of collagenase IV (Sigma-Aldrich, Ml, USA), 0.1 mg / ml of DNasel (Sigma-Aldrich, Ml, USA) and were incubated for 42 minutes at 37 °C. The reaction was stopped by adding PBS with 2 mM EDTA (Invitrogen, MA, USA) and the lysates passed through a filter mesh. Next, tumor cells were isolated using Percoll (Sigma-Aldrich, Ml, USA) gradient. HLA-II molecules were isolated using the HLA-DR-specific antibody (L243) as well as the pan-HLA-ll- specific antibody TU39 (mixed 1 :1 , at least 1 mg or 1 mg per 1 g of tissue, both produced in-house at the Department of Immunology, Interfaculty Institute of for Cell Biology, University of Tubingen) and subsequent elution of the HLA-bound peptides. Peptide eluated were analyzed by nanoflow high- performance liquid chromatography (Dionex UltimateTM 3000 Series liquid chromatography system) and tandem mass spectrometry (Orbitrap Fusion Lumos, Thermo Fisher Scientific, MA, USA). Data- dependent acquisition of data was always conducted in technical triplicates. The raw MS data files were converted into “mgf’ using ThermoRawFileParser and analyzed on MASCOT software with an non- redundant eubacteria UniProtKB / Swiss-Prot protein database (December 12, 2020 with 334,492 entries) and search parameters were 0.5 Da fragment mass tolerance and 5 ppm precursor with no enzyme. All spectra were analyzed manually. We only considered a spectrum valid if we clearly identified a sequence of 4 B-or Y-ions. The samples were also run on Scaffold (Scaffold version 5.2, Proteome Software) software and the "Protein prophet” reported false discovery rates (FDR) was between 2.4 and 5.4. All the acquired sequences were again re-evaluated by comparing them with uniport human proteins, viral proteins, bacteriophage protein database as well as genomic transposable elements (TEs) (data not shown). Synthetic IPdBPs were measured with the same tandem mass spectrometry method and device (Orbitrap Fusion Lumos, Thermo Fisher Scientific) and their MS / MS spectra were compared with those of the immunopeptidome peptides. Since our synthetic peptides were synthesized with modifications at the N-ter (acetylation) and C-termini (amidation) sites, spectra often look quite different in terms of intensities and presence / absence of B -and Y- ion series. The modification changed the charge of the peptides and the character of ionization patterns. The reason for synthesizing peptides with the above-end modifications stems from a convention that we previously established based on the ps-SCLs search algorithm. The latter decamer peptide mixtures, which are used for the unbiased antigen discovery studies, have N-terminal acetylation and C-terminal amidation, and consequently, we always synthesize the predicted peptides with the same ends. The peptides for the sequence validation of the IPdBPs should have been synthesized with free ends. Despite this limitation, peptide sequencing identified the exact same amino acid sequences for 37 IPdBPs via the synthetic peptides. Universal Spectrum Explorer (USE) was used to annotate the spectra and Proteome Discoverer (Thermo Fischer) was utilized to do the research in the raw files.
[0173] The core binding motif of peptides to DRB1 *03:01 , DRB1 *04:02, DRB3*02:02 and DRB4*01 :01 was predicted using NetMHCll 2.3 server, and iceLogo (https: / / iomics.uqent.be / icelogoserver / ) was used for graphical representation of the core binding motifs.
[0174] 16S rRNA gene sequencing
[0175] 16S rRNA gene sequencing of the tumor tissues was conducted by Microsynth AG, Switzerland. Briefly, fresh frozen patient tissues were sent to Microsynth AG, Switzerland. Tissues were cut manually using a sterile scalpel, homogenized using Fastprep 24 (45s, speed 6.5) and total DNA was extracted in using ZymoBiomics DNA Mini Kit D4300 (ZymoResearch). Negative extraction controls were included. Enrichment PCR of the whole 16S gene (primer pair 27F and 1492R) was performed, followed by amplicon library generation (Nextera library preparation protocol) using the locus specific primer pair 341 F (5'-CCTACGGGNGGCWGCAG -3') (SEQ ID NO 071) and 805R (5'- GACTACHVGGGTATCTAATCC -3') (SEQ ID NO 072) and sequencing on a MiSeq platform 2x250 bp v2 (Illumina, San Diego, CA, USA).
[0176] Reads were demultiplexed, trimmed of Illumina adaptor residuals and locus specific bcl2fastq software version v2.20.0.422, FastQC version 0.11 .8
[0177] (https: / / www.bioinformatics.babraham.ac.uk / proiects / fastqc / ) and cutadapt v3.2 (http: / / iournal.embnet.ora / index.php / embnetiournal / article / view / 200), respectively. Trimmed forward and reverse reads of each paired-end read were merged to in-silico reform the sequenced molecule considering a minimum overlap of 15 bases using the software USEARCH version 11 .0.66762. Merged reads were denoised using the UNOISE algorithm implemented in USEARCH to form operational taxonomic units discarding singletons and chimeras in the process. The resulting OTU abundance table was then filtered for possible barcode bleed-in contaminations and against the negative controls using the UNCROSS algorithm. OTU sequences were compared to the reference sequences of the RDP 16S database. Additionally, we used the previously reported data on tumor microbiome with in-depth contamination filtering to further remove potential bacterial contaminants.
[0178] RNA sequencing
[0179] RNA sequencing of the tumor tissue (1635WI) and analysis was conducted as previously reported (Wang, J. et al. ibid). Briefly, RNA-seq was conducted using HiSeq 4000 System (Illumina) at the Functional Genomics Center Zurich. Quantile normalized gene counts were compared with “The Cancer Genome Atlas” (TCGA) GBM cohort.
[0180] Statistical analyses
[0181] All analysis were conducted using GraphPad Prism 8.0. Data are expressed as mean ± SEM. Proliferation results from3H-Thymidine incorporation are always shown with SI mean ± SEM and as mentioned before SI score > 2 is considered significant.
[0182] Data availability
[0183] The TCRVB sequencing results reported in this paper is available and can be accessed via the immuneACCESS database of Adaptive Biotechnologies (link).
[0184] The mass spectrometry immunopeptidomic raw data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD036811 (https: / / www.ebi.ac.uk / pride / archive / projects / PXD036811). Gene expression data for TCGA GBM cohort were downloaded from the Broad GDAC Firehose (Broad Institute of MIT and Harvard. doi:10.7908 / C16T0M0N). Uniprot human proteins (Swiss-Prot-20201202) (https: / / www. uniprot. orq / proteomes?query=(taxonomy id:9606) , Uniprot viruses (Swiss-Prot- 20210305) https: / / www.uniprot.org / uniprotkb?querv=viruses%20AND%20(virus host id:9606), Uniprot bacteria (Swiss-Prot-20201202)
[0185] (https: / / www. uniprot. org / proteomes / ?facets=superkingdom%3ABacteria&query=%2A) and human gut microbiota. The RNA-seq raw data have been deposited to the ENA with the accession code PRJEB56507. Protocol for TCC isolation:
[0186] To generate CD4+ T cell clones, bulk TILs were CFSE-labelled and stimulated with the cognate peptide (10 pM). After 10 days, live proliferative (CFSEdim), CD3+ CD4+ T cells were single-cell sorted into 96- well U-bottom plates. Cells were then expanded using irradiated allogenic PBMCs in the presence of PHA and h-IL-2 in T cell medium (TCM). TCM is based on IMDM medium which contains 5% human serum, 1 % L-glutamin and 1 % penicillin-streptomycin. The medium was changed every 3-4 days and h- IL-2 added each time until day 12. Cells were then subjected to rapid expansion to further expand TCCs. 5 x 104 TCCs were transferred into T25 flasks and were expanded using 3 x 107 irradiated allogenic PBMCs (45 Gy) in T cell medium containing anti-CD3 monoclonal antibody (OKT3). After 1 day, h-IL-2 was added at 50 U / ml and at day 5 the content of the flask was harvested, spun down and resuspended in new T cell medium containing 50 U / ml of h-IL-2. At day 8, cells were split into new T25 flasks and 20 U / ml of h-IL-2 was added. At day 16 cells were harvested, washed and cryopreserved in freezing medium including 90% heat-inactivated FCS and 10% dimethyl sulfoxide (DMSO).
[0187] Sequences Table 1: Peptide sequences
[0188] Table 2: TOR Sequences
[0189] SEQ ID NO 068: TCC88, alpha chain, full nucleotide seq
[0190] ACGGGATATAAGATTGGTTCTCGAAACCATANNNNGNACTGGAAATGGTGACCTCACAGGAAGAT
[0191] GNNNCNNGTAGGAGGCAGCTGTGAGGTNNGGTTCCCCGACGTGGCCCTGCCTGTGGGCTCCCT
[0192] CCATGGCCAACCTGCTATGGACACCAGAGTACTCTGCTGTGCGGTCATCTGTCTTCTGGGGGCA
[0193] GGTCTCTCAAATGCCGGCGTCATGCAGAACCCAAGACACCTGGTCAGGAGGAGGGGACAGGAG
[0194] GCAAGACTGAGATGAANGGNNACAGTCATGTTTACTGGTATCGGCAGCTCCCAGAGGAAGGTCT
[0195] GAAATTCATGGTTANCNNNAGAAAGAAAATATCATAGATGAGTCAGGAATGCCAAAGGAACGATT
[0196] TTCTGCTGAATTTCCCAAAGAGGGCCCCAGCATCCTGAGGATCCAGCAGGTAGTGCGAGGAGAT
[0197] TCGGCAGCTTATTTCTGTGCCAGCTCACGGGACAGGGGTGCAGATACGCAGTATTTTGGCCCAG
[0198] GCACCCGGCTGACAGTGCTCGGTAAGCGGGGGCTCCCGCTGAAGCCCCGGAACTGGGGAGGG
[0199] GGCGCCCCGGGACGCCGGGGGCGTCGCAGGGCCAGTTTCTGTGCCGCGTCTCGGGGCTGTGA
[0200] GCCAAAAACATTCAGTACTTCGGCGCCGGGACCCGGCTCTCAGTGCTGGAGGACGAGCCATCAG AAGCAGAGATCT
[0201] SEQ ID NO 069: TCC88, beta chain, full nucleotide seq
[0202] CTTNANACACTTTCCTTCCTGTTCTCTGGAGATCTTGCAGAAANGAGCCTGCAGTGTTTCCCTTNC
[0203] TCAGCCATGCTCCTGGAGCTTATCCCACTGCTGGGGATACATTTTGTCCTGAGNNAGAGCCCAGT
[0204] CAGTGACCCAGCCTGACATCCTGGAGTTGAGATGTAACTATTCCTATGGGGCAACACCTTATCTC
[0205] TTCTGGTATGTCCAGTCCCCCGGCCAAGGCCTCCAGCTGCTCCTGAAGTACTTTTCAGGAGACAC
[0206] TCTGGTTCAAGGCATTAAAGGCTTTGAGGCTGAATTTAAGAGGAGTCAATCTTCCTTCAACCTGAG
[0207] GAAACCCTCTGTGCATTGGAGTGATGCTGCTGAGTACTTCTGTGCTGTGGGTGTTAACCAGGGA
[0208] GGAAAGCTTATCTTCGGACAGGGAACGGAGTTATCTGTGAAACCCAAGCACATCAAGAAGAGGG
[0209] GTGAAGTGACAAAAGGGAGTTTATTGTGAGGCATCAAACACTGTGATACTCACGGGAGGAGGAA
[0210] ACAAACTCACCTTTGGGACAGGCACTCAGCTAAAAGTGGAACTCAATATCCAGAACCCTGACCCT
[0211] GCCGTGTACCAGCTGAGAGA SEQ ID NO 070: SIN3A
[0212] QPVEFNHAIHYVN
[0213] SEQ ID NO 071 : 341 F Primer
[0214] CCTACGGGNGGCWGCAG
[0215] SEQ ID NO 072: 805R Primer
[0216] GACTACHVGGGTATCTAATCC
[0217] Table 3: TCC 88 genotype
[0218] References
[0219] All references listed below are herein incorporated by reference in full.
[0220] Bessell, C. A. et al. Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insights, 135597 (2020).
[0221] Bessell, C. A. et al. Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insights, 135597 (2020).
[0222] Jelcic, I. et al. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell 175, 85-100.e23 (2018).
[0223] Kalaora, S. etal. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592, 138— 143 (2021)
[0224] Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973-980 (2020).
[0225] Oliveros, J. C. Venny. An interactive tool for comparing lists with Venn’s diagrams. https: / / bioinfogp.cnb.csic.es / tools / venny / (2007).
[0226] Pinilla, C., Appel, J. R. & Houghten, R. A. Investigation of antigen-antibody interactions using a soluble, non-support-bound synthetic decapeptide library composed of four trillion (4 x 1012) sequences. Biochemical Journal 301 , 847-853 (1994).
[0227] Planas, R. et al. GDP-l-fucose synthase is a CD4+ T cell-specific autoantigen in DRB3*02:02 patients with multiple sclerosis. Science Translational Medicine 10, eaat4301 (2018).
[0228] Sospedra, M. et al. Recognition of Conserved Amino Acid Motifs of Common Viruses and Its Role in Autoimmunity. PLOS Pathogens 1 , e41 (2005).
[0229] Sospedra et al., J. Immunol., 176: 1951-1956 (2006) Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079-1084 (2015).
[0230] Wang et al. 2020, Cell 183, 1-18
[0231] Wang et al. R. Tightly linked HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis. Cell, 183(5):1264-1281 ; (2020)
[0232] Wang, J. et al. Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma. Clin Cancer Res CCR-22-1741 (2022) doi:10.1158 / 1078-0432. CCR-22- 1741.
[0233] Yousef, S. et al. TCR Bias and HLA Cross-Restriction Are Strategies of Human Brain-Infiltrating JC Virus-Specific CD4+ T Cells during Viral Infection. The Journal of Immunology 189, 3618-3630 (2012).
[0234] Zhao, Y. et al. Combinatorial Peptide Libraries and Biometric Score Matrices Permit the Quantitative Analysis of Specific and Degenerate Interactions Between Clonotypic TCR and MHC Peptide Ligands. The Journal of Immunology 167 , 2130-2141 (2001).
Claims
Claims1 . An isolated peptide for use in treatment or prevention of recurrence of cancer, in particular for use as a cancer vaccine, wherein the isolated peptide comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008,009, 010, 011 , 012, 013, 014, 015, 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026,027, 028, 029, 030, 031 , 032, 033, 034, 035, 036, 037, 038, 039, 040, 041 , 042, 043, 044,045, 046, 047, 048, 049, 050, 051 , 052, 053, 054, 055, 056, 057, 058, 059, 060, 061 , 062,063, particularly wherein the peptide comprises or consists of a sequence selected from the group of 001 , 010, 011 , 012, 014, 016, 017, 026, 027, 032, 034, 035, 036, 037, 040, 042, 045, 046, 048, 049, 051 , 052, 053, 055, 060, more particularly wherein the peptide selected from the group of SEQ ID NO 001 and 032.
2. A bacterial peptide preparation for use in treatment or prevention of recurrence of cancer, in particular for use as a cancer vaccine, said preparation comprising two, particularly five, more particularly ten, even more particularly fifteen, most particularly all of the peptides designated as SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008, 009, 010, 011 , 012, 013, 014, 015, 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026, 027, 028,029, 030, 031 , 032, 033, 034, 035, 036, 037, 038, 039, 040, 041 , 042, 043, 044, 045, 046,047, 048, 049, 050, 051 , 052, 053, 054, 055, 056, 057, 058, 059, 060, 061 , 062, 063.
3. A nucleic acid expression vector for use in treatment or prevention of recurrence of cancer, in particular for use as a cancer vaccine, the nucleic acid expression vector encoding an isolated peptide as specified in claim 1 .
4. The nucleic acid expression vector for use according to claim 3, wherein the nucleic acid vector encodes a plurality of at least two, particularly five, more particularly ten, even more particularly fifteen, most particularly all of the peptides designated as SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008, 009, 010, 011 , 012, 013, 014, 015, 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026, 027, 028,029, 030, 031 , 032, 033, 034, 035, 036, 037, 038, 039, 040, 041 , 042, 043, 044, 045, 046,047, 048, 049, 050, 051 , 052, 053, 054, 055, 056, 057, 058, 059, 060, 061 , 062, 063; wherein the plurality of peptides is encoded as a concatenate of decapeptides as specified bySEQ ID NO, separated by an amino acid linker consisting of a dipeptide or tripeptide motif consisting of glycine and, optionally, one serine residues.
5. The isolated peptide, the bacterial peptide preparation, or the nucleic acid vector for use according to any one of claims 1 to 4, wherein the peptide, peptide preparation or nucleic acid expression vector is administered in combination with cancer immunotherapy,particularly wherein the peptide, peptide preparation or the nucleic acid vector is administered prior to, concomitant with, or subsequent to, administration of a checkpoint inhibitor / modulator.
6. The isolated peptide, the bacterial peptide preparation, or the nucleic acid vector for use according to any one of claims 1 , to 5, wherein the peptide, peptide preparation or the nucleic acid vector is administered in combination with adoptive T cell therapy, particularly wherein the peptide, peptide preparation or the nucleic acid vector is administered prior to, concomitant with, or subsequent to, administration of a T cell preparation expressing a transgene encoding a T cell receptor polypeptide comprising: c) a CDR3 sequence SEQ ID NO 064 and a CDR3 sequence SEQ ID NO 065; or d) a CDR3 sequence SEQ ID NO 066 and a CDR3 sequence SEQ ID NO 067.
7. The isolated peptide, the bacterial peptide preparation, or the nucleic acid vector for use according to any one of claims 1 , to 5, wherein the cancer is glioblastoma.
8. An isolated decapeptide selected from SEQ ID NO: 001 , 002, 003, 004, 005, 006, 007, 008,009, 010, 011 , 012, 013, 014, 015, 016, 017, 018, 019, 020, 021 , 022, 023, 024, 025, 026,027, 028, 029, 030, 031 , 032, 033, 034, 035, 036, 037, 038, 039, 040, 041 , 042, 043, 044,045, 046, 047, 048, 049, 050, 051 , 052, 053, 054, 055, 056, 057, 058, 059, 060, 061 , 062,063, particularly wherein the peptide consists of a sequence selected from the group of 001 , 010, 011 , 012, 014, 016, 017, 026, 027, 032, 034, 035, 036, 037, 040, 042, 045, 046, 048, 049, 051 , 052, 053, 055, 060, more particularly wherein the peptide is selected from the group of SEQ ID NO 001 and 032.
9. A nucleic acid expression vector encoding an isolated peptide as specified in claim 8.
10. A T cell receptor polypeptide comprising: a) a variable alpha chain comprising a CDR3 sequence SEQ ID NO 064, and a variable beta chain comprising a CDR3 sequence SEQ ID NO 065; or b) a variable alpha chain comprising a CDR3 sequence SEQ ID NO 066, and a variable beta chain comprising a CDR3 sequence SEQ ID NO 067.
11. A nucleic acid expression vector encoding a T cell receptor polypeptide as specified in claim 10 under control of a promoter operable in a human leucocyte.
12. A transgenic human leucocyte comprising the T cell receptor polypeptide according to claim10, or the nucleic expression vector according to claim 11 , particularly for use in treatment or prevention of cancer, in particular for use as a cancer vaccine.
13. A pharmaceutical composition for use in treatment or prevention of cancer, or of recurrence of cancer, comprising the peptide characterised by a sequence specified in claim 1 , and / orthe bacterial peptide preparation as specified in claim 2, the T cell receptor polypeptide as specified in claim 10, or the nucleic acid expression vector as specified in any one of claims 3, 4, or 11 .
14. The pharmaceutical composition for use according to claim 13, wherein the cancer is an immunologically cold tumour, particularly wherein the cancer is selected from a list consisting of pancreatic cancer, prostate cancer, neuroblastoma, or glioma, more particularly wherein the cancer is glioblastoma.
